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ABSTRACT 
INTRODUCTION: Enterococci mainly being commensals in human faeces are 
now considered as an important cause of nosocomial infections. Of the 
infections, the commonly observed are urinary tract infections, abdominal 
infections followed by  bacteremia, endocarditis and meningitis rarely.The initial 
treatment for enterococcal infections has become challenging due to  
development of resistance. The resistance has been observed mainly against 
aminoglycosides due to the presence of bi-functional gene.VRE strains are 
mostly isolated from patients with recurrent bacteremia, endovascular infections 
leading to increase deaths in the patients. Limited treatment options are available 
for drug resistant strains. 
AIM: To isolate and speciateenterococcal isolates from clinical samples, study 
the antibiotic susceptibility pattern and the genotype associated with the 
aminoglycoside and vancomycin resistance. To screen the high risk patients in 
critical care areas for VRE from stool samples.  
MATERIALS AND METHODS: Enterocccus isolates obtained from various 
sections were characterized by conventional phenotypic methods. The antibiotic 
susceptibility was studied by disc diffusion method. The resistant strains were 
further confirmed by MIC using automated methods following which the 
genotypic analysis was done. Screening of VRE carriers from high risk group 
was done using rectal swabs and results interpreted after inoculation in chrome 
agar. 
RESULTS & CONCLUSION: The incidence of enterococci was 2.5% in 
which around 86.4% were obtained as pure isolates. Among the species 
E.faecalis was the maximum. The urinary isolates exhibited sensitivity of around 
92.3% to nitrofurantoin and among the non - urinary isolates the maximum 
sensitivity was for linezolid followed by vancomycin and other antibiotics. The 
molecular study showed van A to be most common gene  with vancomycin 
resistance(71.42%), and bifunctional gene among the aminoglycoside 
resistance(96%).The incidence of VRE carriers was 3%.The increase in 
resistance patterns in hospital strains reflects the limited treatment options that 
might pose a risk in future in managing complicated cases. 
KEYWORDS: Enterococci, speciation, antibiotic resistance, vancomycin, 
aminoglycosides, genotype, vancomycin resistant enterococci(VRE) carriers. 
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Introduction 
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Enterococci mainly being commensals in human faeces are now 
considered as an important cause of nosocomial infections. Of the infections, the 
commonly observed are urinary tract infections, abdominal infections followed 
by surgical site infections, bacteremia, endocarditis and meningitis rarely. They 
are referred to as the third organism in causing nosocomial infections in the 
west.
1 
Enterococci being the commonest micro flora of both humans and 
animals share their source of origin .They have been isolated from variety foods 
including cheese, fish, sausages, beef and pork. Studies have been reported that 
enterococci have been isolated from various clinical and environmental samples 
all over the world. Among the isolates obtained clinically it has been observed 
that Enterococcus faecalis has been the predominant species clinically.
2,3 
         Enterococcal  infections have been referred to as tough, tenacious and 
troublesome infections.
4
 In the past years there has been an increase in the 
prevalence of enterococcal infections in hospitals and of particular concern is 
the emergence of antimicrobial resistant strains. Being second commonest 
organism behind the abdominal and pelvic infections, third in causing blood 
stream infections, cases have also been reported in causing CNS and neonatal 
infections.         
        Reports have been confirmed with their association with clinical conditions 
including respiratory tract infections, osteomyelitis and cellulitis.
5
 Enterococci 
was initially regarded as the disease causing agent in the early nineties. But now 
3 
 
various reports have been established reporting them as the second commonest 
pathogen.
6 
Enterococci separated as gram positive cocci initially  were later 
classified under the genus Streptococcus. Based on a series of biochemical tests 
and Lancefield serological typing enterococci were classified as group D 
streptococcus separating them from non-enterococcal group D streptococci.
7,8
 In 
1930s, Sherman recommended the term “enterococcus” to be used specifically 
for the streptococci species that had the following characteristics, growth at 10 
and 45 degree Celsius, ph 9.6, 6.5% NaCl and survival at 60 degree for 30 
minutes. They also had the ability to hydrolyze esculin with 40% bile. In 1980, 
they had their own genus enterococcus.
9 
           Species identification becomes essential for investigating outbreaks in 
case of nosocomial infections and also susceptibility pattern varies accordingly 
which is also helpful in clinical management of infections due these agents.
10 
 Infections caused by enterococcal pathogens were initially being treated 
with the combined treatment of cell wall active agents as penicillins and 
aminoglycoside as the synergistic effect was effective.  But now due to the 
development of antibiotic resistance as high level aminoglycoside resistance, 
beta lactamase production and also resistance to vancomycin have led to serious 
concern in management of these nosocomial pathogens.
11 
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Resistance spread among the enterococcal isolates in hospitals has led to 
treatment failure. Also the excess use of antibiotics and the pressure due to 
colonization play a major role in the drug resistance in these species.
12 
Vancomycin resistant enterococcus was initially reported in 1980s , after 
which there was a increase in the incidence of its spread .The main phenotypes 
associated with its spread are Van A, Van B and Van C. Van A and Van B are 
mainly associated with E.faecalis and E.faecium.Van C is noted in E.gallinarum 
and E.casseliflavus. Among the phenotypes Van A is predominantly associated 
in the resistant strains.  
VRE strains are mostly isolated from patients with recurrent bacteremia, 
endovascular infections leading to increase deaths in the patients. Vancomycin 
resistance and penicillin resistance are often seen co-existing which makes the 
treatment harder.
1 
          Resistance development in enterococcus against glycopeptide antibiotics 
gets transferred from them to other bacterial pathogens which include 
Staphylococcus aureus, Streptococci, Listeria monocytogenes.
13 
Thus due to the recent emergence in association with significant clinical 
infections and development of resistance, enterococci have gained importance. 
Studies are thus required especially in tertiary care hospitals for appropriate 
isolation, identification and speciating them. Antibiograms should also be 
followed up in accordance to the species. Emergence of VRE needs to be 
checked and limit its spread in hospital environment.  CDC also stresses the 
5 
 
control of VRE in hospitals by educating the staff in detecting VRE early, 
reporting them and action plan taken promptly. 
My study aims to isolate, speciate the enterococcus in a simplified 
manner and also to study the drug sensitivity and resistance patterns among the 
isolates obtained. 
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Review of literature 
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 Enterococcus is also referred to as the „streptococci of fecal origin‟. The 
term „Enterocoque‟ was used for the intestinal origin of these gram positive 
bacteria occurring in pairs and short chains which was published in a paper 
presentation in France in 1899. In the same year a case of endocarditis was 
reported which was believed to be caused by Micrococcus zymogenes. Later 
studies demonstrated it to be hemolytic Enterococcus.
14
  
 Enterococcal species have gained importance by becoming one of the 
most common pathogens in causing infections associated with urinary tract, 
blood stream, CSF and infections associated with soft tissues. With the 
involvement of resistance to clinically significant drugs as vancomycin and 
aminoglycosides has increased their importance due to the risk of spread of 
resistance to other sensitive strains. 
         In 1906 the term Streptococcus faecalis was used for the same. 
Fermentation of mannitol and lactose by these organisms was also demonstrated 
in them. Streptococcus faecium was demonstrated in 1919 which differed from 
other species in their biochemical reactions. Streptococcal durans was proposed 
in 1935 whose fermentation reactions showed variations.
15
       Enterococcus was 
grouped into those gram positive organisms that grew at 10 and 45 degrees, pH 
9.6 and 6.5% NaCl, also survived heating for 30 minutes at 60 degree.
4
      
      The above classification also matched Lancefield‟s serological scheme that 
was developed in 1930 such that it reacted with group D antisera.
16
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        Streptococcus avium was added to the group in 1967. In the year 1970 a 
separate genus on the basis of cellular arrangement of Streptococcus faecalis and 
faecium was recommended to be named as Enterococcus.
15 
        Discussions on enterococcus was also done by various authors.
17
 It was in 
the year 1984 Streptococcus was divided into Enterococcus, Lactococcus and 
Streptococcus. Based on the studies done a large number of species were 
included in the genus accordingly. The various species included in this genus 
were E.avium, E.durans, E.casseliflavus, E.gallinarum E.faecium E.faecalis, 
E.hirae, E.malodroratus, E.mundtii based on the DNA-DNA  hybridization. 
New species as E.raffinosus and E. solitarius were also discovered.
18
 Motile 
enterococci discovered initially were called Streptococcus faecium subspecies 
mobilis was renamed as Streptococcus faecium var casseliflavus.
19
 
         Biochemical and genetic data shows that the strains S.casseliflavus, 
S.durans ,S.faecalis sub sp.malodoratus and a few others have close relations to 
the members of Enterococcus as described initially. Studies revealed that the 
above mentioned species were renamed under genus Enterococcus as E.avium, 
E.casseliflavus, E.durans, E.malodoratus and E.gallinarum respectively.
20  
In 
1985 E.hirae, a new species was identified. 
21
 E.solitarius was also identified 
from human sample.
22
 E.rattus was isolated from the intestine of neonatal 
diarrheal rats and thus named accordingly. E.porcinus was identified from 
pigs.
23 
Recently new species E.gilvus and E. pallens were identified in the year 
2002.
24
 E.phoeniculicola was also included under the genus.
25
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TAXONOMY:
26
 
Kingdom  :    Bacteria 
Phylum    :     Firmiculates 
Class       :      Bacilli 
Order      :     Lactobacillales 
Family    :     Enterococcacceae 
Genus     :     Enterococcus 
GENUS DEFINITION AND TAXONOMY: 
 Enterococci as a genus hydrolyze esculin in the presence of 40% bile. 
They are catalase negative and are fermentative with lactic acid as the end 
product of glucose fermentation without the production of any gas. Majority of 
the strains about 95% have the group D antigen in their cell wall. Pyrrolidonyl -
3-naphthylamide (PYR) hydrolysis is a special feature of this genus. DNA 
content is 38-45% of these genus. About 28 species are currently in included 
under them. Enterococcus faecalis is the type species of this genus.
15
                        
Molecular information gathered with the help of 16S RNA sequencing 
explained the relationship between the related species. The grouping of the 
species was also based on this method. A dendrogram showing the phylogenetic 
position of Enterococcus was made.
27 
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16S rRna DENDROGRAM OF PHYLOGENETIC POSITION OF 
ENTEROCOCCUS SPECIES: 
     
 
 
 
 
 
 
HABITAT: 
         Enterococci are found everywhere in the environment and survives harsh 
conditions. They are found in the plants, soil, water, animals and food. Also 
found in the birds, insects and reptiles. In human beings they are mainly 
inhabitants of intestinal tract followed by the genitourinary and mouth.
15 
 Their 
concentration in stool varies from 10
5
-10
7
 CFU/gm of faeces. Studies have been 
published suggesting that Enterococcus faecalis is observed in high numbers 
than others in the faecal samples.
28
 The other species were isolated from the 
intestinal tracts of various animals and unusual causes of infections in humans.
26 
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MORPHOLOGY AND CULTURAL CHARACTERITICS: 
 Enterococcus are gram positive bacteria occurring in pairs and short 
chains measuring around, 0.6 – 2* 0.6-2.5µm.With the exceptions of 
E.casseliflavus and E.gallinarum other species are non-motile. Being facultative 
organisms enterococci have the ability to grow at a temperature range of 10 to 45 
degree and survives heating at 60 degree for 30 minutes.
29
 Growth in blood agar 
shows colonies ranging from 1-2 mm in diameter or smaller. E.faecalis is non 
haemolytic in sheep blood agar but can vary to haemolytic form when rabbit, 
horse or human blood is used.
26
 
 The alpha hemolytic property of enterococcus species is mainly   due to 
the peroxide production of the species. The greenish discoloration of the blood 
agar is due to the peroxide action and not because of the synthesis of alpha toxin. 
The pigment production of certain species including E.casseliflavus, E.gilvus, 
E.pallens, E.mundtii and E.sulfureus is also observed.
15
 In Mac Conkey agar tiny 
(0.5-1mm) magenta pink colonies are seen due to lactose fermentation. Their 
growth is also well appreciated in media with increased salt content i.e. 6.5% 
NaCl which aids in differentiating it from others.
30,31
       
 Growth has also been noted in selective media which includes bile esculin 
agar in which colonies are observed greyish surrounded by black halo that 
occurs as a result of hydrolysis of esculin to esculitin that reacts with ferric 
ammonium citrate to give black colour.
15
 Other special medias employed are 
Pfizer-selective enterococcus agar, oxoline-esculin agar, selective media with 
12 
 
vancomycin for VRE screening.
27 
Enterococci being aerobe and facultative 
anaerobe need certain growth requirements which includes methionine, histidine, 
tryptophan and isoleucine but some require other amino acids as glutamate, 
glycine and leucine.
15
 
SPECIES IDENTIFICATION: 
 Enterococcal species causes a wide range of clinical diseases. Speciation 
is not mandatory for all Enterococcal infections. The majority of the isolates are 
associated with urinary tract infections in which case a genus level identification 
along with antibiotic sensitivity with antimicrobials including Penicillin, 
Ampicillin and Vancomycin is satisfactory. In conditions like endocarditis, 
speciation is necessary mainly between E.faecalis and E.faecium for the purpose 
of treatment. E.faecium is noted to be more resistant to Penicillin group and most 
of the clinically isolated VRE (Vancomycin resistant enterococci) are faecium 
species. The speciation depends on a wide range of biochemical reactions which 
includes production of acid from sorbitol, glycerol, D-galactose, melibiose, L-
arabinose. Certain special characteristics are exhibited by few species 
characteristically which includes motility by E. casseliflavus and E. gallinarum. 
Pigment production by E.casseliflavus and E. mundtii.
18
 
 It is necessary to identify the motile species because they have the feature 
of being intrinsically resistant to antimicrobials as Vancomycin at low levels and 
if improperly treated can lead to complications and unresponsiveness in patients 
The tests apart from motility to identify E.gallinarum and E.casseliflavus are 
13 
 
pigment production and failure to ferment inulin. These are mainly associated 
with infections in immunocompromised and organ transplant patients. 
32
  
 Enterococcus are classified as gram positive, catalase negative organisms 
with positive L-pyrrolidonl beta-naphthylamide (PYR), LAP(Leucine 
aminopeptidase), and presence of growth at 45 degree and 6.5% NaCl. 
 The species are classified into 5 groups which are as follows:
26
  
Group 1 
E. avium, E. gilvus, E. malodoratus, E. raffinosus E. pallens, ,E. 
saccharolyticus E. pseudoavium 
Group 2 
E. casseliflavus, E. gallinarum E.faecalis, E.faecium,  E.mundtii, 
E.haemoperoxidus 
Group 3 E.dispar, E. durans, E. hirae, E. ratti, E. villorum 
Group 4 E.asini, E. cecorum, , E. sulfureus, E. phoeniculicola 
Group 5 E. canis, E. columbae, E. moraviensis. 
 
Identification of enterococcal species presumptively is based on: 
30 
1) Catalase test 
2) Salt tolerance test 
3) Heat tolerance test 
4) Bile esculin test 
5) PYR test 
6) Arginine test 
7) Carbohydrate /Sugar fermentation test 
8) Potassium tellurite test (0.04%) 
14 
 
9) Vogues – Prosker (VP) test 
1) Catalase test: Enterococci do not possess the enzyme cytochrome oxidase 
thus are catalase test negative on testing with hydrogen peroxide. Few of the 
strains do produce delayed reaction categorizing them as pseudo catalase 
producers.  
15    
 
2) Salt tolerance test: When colonies are inoculated in 6.5% NaCl broth, 
increase in turbidity after overnight incubation indicates positive test.
30 
  
Modifications in the form of rapid test has been proved to be effective in species 
isolation.
31  
 
3) Heat tolerance test: In 1914,
 
studies have demonstrated heat tolerance to be 
one of the characteristic feature exhibited by enterococcus that helps it in being 
differentiated from other species.
16,26
 It survives heating for 30 min at 60 degree 
distinguishing it from other Streptococcal species.
30   
4) Bile esculin hydrolysis: This test proved to have a sensitivity of 100% and 
specificity of 97% .
15,33  
5) PYR test: (Hydrolysis of L- pyrrolidonyl beta – naphthlamide test): This test 
was used as a presumptive identification for Enterococci and group A beta 
haemolytic streptococci. Initially the test was 20 hour test but now 4 hours 
incubation in PYR broth at the end of which PYR reagent added gives the 
result.
34 
15 
 
6) Arginine test: Studies have proved that hydrolysis of arginine was used as a 
dependable test in species identification.
19 
7) Carbohydrate fermentation test: A wide range of carbohydrates as lactose, 
sucrose, raffinose, sorbitol, maltose, trehalose, arabinose, mannitol, inulin, 
salicin were used for speciation.
18,19 
Initially 26 tests were done for speciation by 
which E.faecium, E.avium, E.casseliflavus, E.equinus were isolated.
17 
Later other 
tests as sorbose fermentation, pyruvate utilization and arginine deamination were 
added.
17,18 
In 1989, Facklam and Collin presented a simplified scheme for the 
identification of species through conventional tests.
18
 
 
8) Potassium tellurite test: Studies showed that when 0.04% of potassium 
tellurite was added to the agar, a few of the enterococcal species had the 
property to reduce tellurite forming black colonies.
17,18  
9) Voges- Prosker (VP) test: Tests were done on enterococcus for testing the 
production of acetoin and comparing with rapid Strep system results.
35 
 Various 
methods were compared and Coblatz method proved to be the best in 
differentiation of the species.
30 
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ALGORITHM FOR IDENTIFICATION OF ENTEROCOCCI 
Enterococcus species 
                                     (Bile aesculin +, 6.5% NaCL +, PYR+) 
                                                                
                                                 Mannitol 
 
                 +                                                                                              - 
Arginine dihydrolase/ Sorbose                                                           Group 3 
              Sucrose/ Raffinose 
-/+                                                  +/-                                                                             
 
Group 1                                     Group 2         +/+                                           -/- 
                                                                Growth in Pyruvate         Growth in 
Pyruvate                     
                     
                                                               +                            -        +                             
- 
 Arabinose/Raffinose                         E.dispar              E.hirae    E.faecalis         
E.durans 
+/+ = E.raffinosus                                                                         
+/-  = E.avium                                                                               (Asaccharolytic 
variant) 
-/+ = E.malodoratus                                   
-/- = E. pseudoavium                     Motility                                        
                                        
                                           +                                                            - 
                                      Yellow pigment                                 Arabinose 
 
                                   +                               -                 +                                    - 
                         E. caseliflavus     E.gallinarum       Yellow pigment          Lactose 
                                                                                                  
                                                                       
                                                                      +                                 - 
                                                              E. mundti             E. faecium 
 
                                                                                          +                              - 
                                                                             E.faecalis         Sucrose  /     
 
                                                                                                                                                                                                                           
          
+/+ 
-/- 
E.seriolicida 
Melezitose 
E.solitarius 
17 
 
Commercial systems are now available for the identification of Enterococcal 
species which includes API 20S(Analytab Products, Plainview, N.Y), GPI 
(Gram positive identification) , Vitek Systems Inc.,Hazelwood,Mo.), the Rapid 
Strep System (API). The advantages of these systems is that they provide the 
result faster than the biochemicals that consume more time provided enough 
inoculum is present. Studies have reported that species as E.faecalis, E. faecium, 
E.avium and E. durans are identified properly.
36,37,38
          
          Molecular studies as in DNA hybridization also confirmed the genetic 
variations between the E.faecalis and E.faecium. Estimated that approximately 
6.4% of this genome is in conjunction with cell – surface proteins and about 
22.6% of the differences between the species are observed in these genes.
27
  
PHYSIOLOGY:
 
          Enterococcus is a highly resistant bacteria and can even grow in 
conditions when the temperature, pH and salt concentration is increased. The 
effect of temperature is mostly observed in the lag phase of the growth cycle 
while the stationary phase being more resistant to it.
39
 The resistance of 
Enterococcus to pH , is believed to be due to the durability and impermeability 
of the cell membrane to acid and alkali. 
40 
The resistance nature depends on both 
the phase of growth and temperature of the species.
41 
The amine production is 
also been associated with temperature, growth and pH .Studies suggest that 
decarboxylase activity is observed at acidic pH but this is not favourable for the 
18 
 
production of biogenic amine. The amine production is not affected by 
temperature directly but its effect on the cell affects the production of amine.
39      
  
 ECOLOGY AND EPIDEMIOLOGY: 
          The occurrence of Enterococcus species varies widely from animal, 
human and environmental sources. They form a part of microflora in human 
intestinal tract (E.faecalis and E.faecium), where as E.faecium is predominant in 
animals whereas E.mundtii and E.casseliflavus is observed in plants. 
42 
 
 The distribution of Enterococcus varies widely throughout Europe. In the 
UK, they have been observed in both the environmental and also the clinical 
samples from the patients. Sweden shows an increased rate of E.hirae similar to 
Denmark.
43    
Studies from India suggest that E. faecium and E.faecalis are the 
predominant species in India.
44    
       
 The Enterococcus species have become the second causative organisms 
of hospital infections
20
 and the third causative organism in United States.
45
 
Enterococci show a low level resistance to antimicrobials as penicillin, 
cephalosporins, aminoglycosides and lincosamides.
46
 Attention to these species 
recently is mainly due to the resistance pattern demonstrated by them to a wide 
range of antibiotics mainly aminoglycosides, ampicillin and vancomycin. Beta 
lactamase production is also been reported among these species.
47 
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VIRULENCE FACTORS AND PATHOGENESIS:
 
The virulence factors seen in Enterococcus based on the various studies 
are:
27,48-51 
1) Cytolysin/ Haemolysin 
2) Aggregation substance 
3) Extracellular surface protein 
4) Lipoteichoic acid 
5) Coccolysin  
6) Gelatinase 
7) Extra cellular superoxide 
8) Biofilm 
9) Pili 
10) Microbial surface components recognizing adhesive matrix molecules 
(MSCRAMM) 
11)  Cell wall and Capsular polysaccharide 
12)  Glycolipids  
 Cytolysin: Enterococci possessing this factor has the ability to cause lysis of 
horse, human and rabbit erythrocytes. This is believed to be more virulent  in 
animals than human beings.
52
 The cytolytic action is due to the post 
translationally modified protein toxin seen in almost 60% of faecalis isolates.
53
 
Experiments in rabbits have demonstrated that endocarditis due to Enterococcal 
20 
 
species with cytolytic action can result in increased mortality in comparison with 
those strains without it.
54 
Aggregation substance: It causes the efficient donor – recipient contact 
resulting in effective plasmid transfer through conjugation. It is actually a 
pheromone inducible protein located on the surface of E.faecalis that results in 
mating. The various functions associated with this substance are adhesion to 
extracellular matrix (ECM) protein, attachment to host cells and increasing the 
hydrophobicity of the cell surface. Studies have demonstrated that in vitro that 
prior immunization of rabbits with these substances does not provide any 
protection against endocarditis caused due to them. Studies have confirmed that 
its role in pathogenesis is due to evasion of immune system.
52 
EXTRA CELLULAR SURFACE PROTEIN: This is a cell-wall associated 
protein seen in the virulent strains believed to originate from E.faecalis with Van 
B genotype. It is encoded by the esp gene present on the surface of the bacteria. 
In conditions associated with immunodeficiency it retracts the surface protein 
that results in further immune evasion.
55 
LIPOTEICHOIC ACID: It forms the group D antigen of the Enterococcal 
species. It causes the production of tumour necrosis factor and also interferon 
resulting in modulation of immune response. 
COCCOLYSIN: It constitutes the extracellular metalloendopeptidase that 
inactivates the vasoactive peptide endothelin.
26  
21 
 
GELATINASE: Enterococci producing gelatinase are found to be is associated 
with peritonitis, endocarditis and endophthalmitis in rabbits. It is an extracellular 
zinc metalloprotease that hydrolysis gelatin, casein and collagen.
56
 This property 
is encoded in an operon which is up regulated by quorum sensing by the fsr 
which is a regulator locus.
48
 This property can be demonstrated in vitro by 
inoculating Enterococci in freshly made yeast extract agar plates with gelatin 
and incubating at 37 degree overnight followed by cooling for two hours 
Positive activity is denoted by a halo around the colonies.
52
 
EXTRA CELLULAR SUPEROXIDE: It is an important factor associated 
with enterococcal infections causing bacteremia.
49
 This feature provided the 
survival advantage of E.faecalis along with Bacteroides fragilis in mixed 
infections.
57 
BIOFILM: The production and adherence of Enterococcal species due to 
biofilm formation on various materials have been demonstrated. There appears 
to be a direct relation between the production of biofilm and its ability to bind 
with stents, catheters, silicon gastronomy devices and other medical devices. 
Various studies have been put forth regarding the prevalence of biofilm 
production among Enterococcal species. Studies report that about 80% 
E.faecalis and 48% E. faecium are associated with biofilm production isolated 
from infected patients.
58
A wide range of factors including the presence of 
glucose, serum, availability of CO2 and iron , osmolarity, pH have an effect over 
the production of biofilm in these virulent strains. The carbohydrate metabolism 
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influences the development of biofilm among various gram positive cocci 
especially E.faecalis. Studies have shown that 1% glucose supplemented with 
trypticase soy broth(TSB) helps in the demonstration of biofilm better than 
media without it. It has been proved that glucose dependant regulator (fsr) is 
responsible for biofilm production. Apart from fsr other factors such as 
Enterococcal surface protein (esp), secretory metalloproteae gelatinase (gel E), 
biofilm associated pili and biofilm enhancer are proved to produce biofilm.
59 
PILI: The presence of pili in Enterococcus is responsible for the adhesion of the 
bacteria to human cells and result in disease. There are genes that encode these 
pili as PGC (pilin gene clusters) that are necessary for its assembly. These along 
with the presence of biofilm formation results in the pathogenesis of 
experimental endocarditis and also urinary tract infections. Studies have been 
stated that expression of these pili gene is more in E. faecium than E.faecalis 
species. 
MSCRAMM: Microbial surface components recognizing adhesive matrix 
molecules play an important role in the colonization of Enterococcus. Among 
the species E.faecalis claimed to have 17 and E.faecium had 15.But only 7 
among them are studied in detail. These include: 
a) Ace(adhesion of collagen in E.faecalis) 
b) Fss 1, Fss 2, Fss 3(E.faecalis surface protein) 
c) Acm(adhesin of collagen of E.faecium) 
d) Scm(second collagen adhesion of E.faecium) 
23 
 
e) EcbA(E.faecium collagen binding protein A) 
        The presence of these virulence factors have increased the severity of 
infections caused by them. Of these Ace was seen in endocarditis patients 
experimentally. EcbA was observed in nosocomial infections due to E.faecium.
51 
CELLWALL AND CAPSULAR POLYSACCHARIDE: The recognition of 
polysaccharide antigen on the bacterial surface (Epa) by patients with systemic 
enterococcal infections has been demonstrated in various studies. Much 
information is not available for its structure and just that is has been localized 
inside the cell wall.
60   
This is directly related to the pathogenicity as any 
alteration results in reduction in biofilm formation.
61 
GLYCOLIPIDS: The presence of glycolipids plays an important role in the 
pathogenesis of clinical infections. They form a permeable layer between the 
environment and cytoplasm. One glycolipid in particular DGlc-DAG is present 
mainly in E.faecalis constituting about 37% of the polar lipids present in the cell 
membrane. The mutant incapable of producing this glycolipid could not produce 
the disease.
51 
INFECTIONS CAUSED BY ENTEROCOCCI:  
          E.faecalis and E.faecium are the two species predominantly associated 
with clinical infections. Studies have been reported suggesting that E.faecalis 
accounts for around 80 to 90% followed by E. faecium that comprises of about 
15% of the infections identified.
15 
Other species that can cause infections include 
24 
 
E.casseliflavus, E. avium, E.durans, E.gallinarum, E.casseiflavus, E.hirae, 
E.pseudoavium, E.raffinosus, E.solitarius, E.dispar, E.malodoratus, 
E.saccharolyticus, E.serioicida, E.cecorum, E.flavescens. The infections caused 
by these species include urinary tract infections, endocarditis, intraabdominal 
and intra pelvic abscesses, blood stream infections and wound infections 
following surgery. Occasionally they are also isolated in central nervous system 
and neonatal infections. Cases have been reported them to be causative 
organisms in osteomyelitis and respiratory infections.
 
URINARY TRACT INFECTIONS:  
          Enterococci are found to be the most common cause of infections 
involving the urinary tract. Infections range from uncomplicated to complicated 
UTI s involving cystitis, prostatitis, pyelonephritis and perinephric abscess. Most 
of these infections have been reported in hospitalized individuals.
62
 Studies show 
that the percentage of significant bacteriurea of urine sample cultures which is > 
10
5 
has increased from 11% to 20% in catheterized individuals than in 
midstream urine cultures.
63
 The Center for Disease Control‟s National 
Nosocomial Surveillance Study rates enterococci as being the third common 
cause of nosocomial UTI.
1 
INTRA- ABDOMINAL AND PELVIC INFECTIONS: 
          Enterococci form part of the intestinal flora normally and account for 
around 17% of vaginal cultures in the female. Enterococci are important 
pathogens associated with intra-abdominal infections and sepsis. Cases have also 
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been reported indicating them to be the causative organisms in spontaneous 
peritonitis in patients with cirrhosis and nephrotic syndrome. It also results in 
peritonitis in patients on long term dialysis.
64
 They have also been associated 
with salphingitis, maternal infections as endometritis and post Cesarean abscess 
formation.
65  
ENTEROCOCCAL BACTEREMIA: 
           Bacteremia due to enterococcus accounts to be the third most common 
cause of blood stream infections.
8 
The most common source of infection is 
endocarditis and if not its urinary tract infections. Studies suggest that patients 
had underlying source of infection as urinary or intravascular catheter, 
abdominal or pelvic surgery, burns, and peripartum maternal infections when 
presenting with bacteremia.
66-69
Mortality rate is high which may be related to the 
underlying risk factors.
1   
ENTEROCOCCAL ENDOCARDITIS: 
          Enterococci accounts for nearly 15% of endocarditis due to bacterial 
causes. The main pathogen is E.faecalis but other species also play a role in this 
manifestation. Individuals above 65 years are more prone to enterococcal 
endocarditis. 
1
 The other risk factors involved are proceeding UTI„s or 
catheterization, biliary infections. Studies have been reported suggesting that 
38% of women had prior genital infection or instrumentation. It can present as 
acute or chronic condition. It‟s mostly associated with an underlying heart 
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disease but this does not form a prerequisite.
70 
Enteococcal endocarditis has also 
been reported in drug addicts. The valves mainly affected are mitral and aortic.
71  
 NEONATAL INFECTIONS: 
 Group B streptococci and Escherichia coli are the main pathogens causing 
infections in neonates, but it has been recorded that Enterococcal species can 
also cause infections in this age group. Nosocomial spread is strongly associated 
with these infections.
1 
Infants with these infections had a remarkable feature of  
previous premature delivery, low birth weight and some cases long standing 
central line was recorded.
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CENTRAL NERVOUS SYSTEM INFECTION: 
 Apart from neonates enterococcal species can cause meningitis in older 
children and adults rarely.
 
 Most of them have a prior risk factor as an invasive 
procedure or long term infection and on prolonged antibiotic.
1 
Cases have been 
reported them to be associated with brain abscess. The effect is mainly due to the 
haematogenous spread from a localized infective site as sinusitis or otogenic 
origin.
73  
 
NOSOCOMIAL INFECTIONS AND SUPERINFECTIONS: 
 Studies have proved that enterococcal species to be the major cause of 
infections acquired from the hospitals.
74
 The recent studies proved that person –
to – person transfer being the important source. It‟s been noted that treatment 
with antimicrobials without enterococcal activity has led to superinfections. 
27 
 
 The use of polymyxin aerosol in the prevention of pneumonia associated 
with Pseudomonas has led to the spread of Enterococcal induced respiratory 
infections. Studies from the west have reported the increase in the infection rate 
with liver transplant patients.
1
 
SHIFTING SPECTRUM OF ENTEROCOCCAL INFECTIONS:
8   
 
 The ratio of E.faecalis to E.faecium was nearly 10:1. But this ratio has 
been declining. The change has been remarkedly noted in bacteremia infections 
in which there is a decrease in the ratio from 3.7:1 to 1.9:1. The E.faecium is 
found to be increasing in these isolates. Now there has been a rise in the VRE in 
which E.faecium species dominates. Studies have reported a 47% increase in the 
VRE isolates. The cause of concern is the emergence of pan-resistant species 
that show resistant to ampicillin, vancomycin, gentamycin and streptomycin. 
PHENOTYPIC RESISTANCE: 
 This type of resistance includes intrinsic resistance of Enterococci to 
penicillins, cephalosporins, lincosamides, nalidixic acid, low level 
aminoglycosides, low level clindamycin and cotrimoxazole.
4 
 
The acquired resistance includes the resistance acquired genetically. 
GENETIC MECHANISM: 
 The resistance among the enterococcal species varies. It has been 
observed that E.faecalis has low level resistance to ampicillin and vancomycin 
compared to E.faecium. Gene responsible for resistance can be carried on the 
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pheromone and be transferred between the two species. The motile species 
account for less than 2% but have the property of intrinsic resistance. These 
species have found to be associated with infections in immunocompromised 
individuals.
8   
Conjugative gene transfer occurs by spread of transposons between 
gram positive and gram negative bacteria. Low frequency transfer has been 
noted from E.faecalis and Listeria species in gnotobiotic mice.
75
The other 
mechanism of transfer of genetic matter is through phages but spread of 
virulence strains is not recorded.
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SENSITIVITY TESTING:
 
 
The antimicrobials used in testing against enterococcus include 
ampicillin, penicillin, vancomycin, amoxycillin clavulanic acid, erythromycin, 
high level gentamycin and linezolid. In case of urinary isolates norfloxacin, 
nitrofurantoin and tetracycline is used along with the above and penicillin is not 
used.
77 
Initially MIC s for ampicillin and penicillin as 8(moderately sensitive) 
and 16(resistant)µg/ml was reported but recent CLSI (2014) suggests <=8 as 
sensitive and not moderately sensitive.
1,77 
But for vancomycin MIC <=4 ,8-16, 
>=32 µg/mg is considered sensitive, moderately sensitive and resistant 
respectively. If disc is used (30µg disk) a zone of >=17, 15-16, <=14 is 
interpreted as sensitive, moderately sensitive and resistant respectively.
77
  
 Isolates from patients with endocarditis and life threatening infections as 
meningitis, aminoglycoside activity is to be determined. MIC of greater than 
2000µg/ml proves HLR.
1  
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1) High- content disc: 
           Studies were reported stating that the use of high content aminoglycoside 
disc were effective for screening HLR enterococcal species.
78 
Comparative 
studies for MIC determinants on Muller- Hinton plates using high content 
gentamycin disc(120µg) and tobramycin along with tobramycin(300µg) was 
done.
1 
 Further studies used gentamycin and kanamycin with120µg along with 
300µg of streptomycin. Strains without HLR activity had zone size >=12.
 
The 
disc diffusion method was able to detect all the gentamicin resistant strains but 
only 94% of streptomycin resistant strains.
79 
2) Agar screening: 
            Most of the laboratory usually does not perform MIC or synergy testing 
as a routine, other screening test for HLR is sought. Inoculation of enterococcal 
colonies in dextrose phosphate agar with 2000µg of aminoglycoside per ml was 
effective in detecting the presence or absence of synergy.
80  
Studies further 
proved that irrespective of the media used with both gentamycin and 
streptomycin; good results were obtained when spot inoculated with 10
4
-10
6
 
CFU per spot.
81  
3) Broth dilution: 
          In this method only one concentration of aminoglycoside in micro dilution 
well was used. Studies were done using 500µg of gentamycin in Muller- Hinton 
broth along with Ca and Mg with an inoculum of 5*10
5 
CFU/ml.
82 
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Recommendations for HLGR to aminoglycosides:
1 
1) Single concentration agar plate and the disk diffusion are highly for 
detecting HLR to gentamycin and streptomycin. 
2) Broth dilutions are acceptably good except that there is a possibility to 
miss a few strains with streptomycin 2000µg/ml. 
3) Caution must be employed on using automated systems as comparison 
with standard methods is not evaluated. 
4) To test for aminoglycosides apart from gentamicin and streptomycin is of 
little significance as most of the data is based on these. Strains with 
HLR(high level resistance) to gentamicin alone without HLR to 
streptomycin due to enzymatic action of 2”-APH-6‟-AAC in observed. 
TYPING METHODS:
15  
          Typing for Enterococci has become essential as there has been a rise in the 
number of clinical infections caused by them. Adding on to this is the resistance 
pattern exhibited by these species which justifies the epidemiological purpose in 
studying these isolates by typing them. 
Phenotypic methods of typing:
83 
1) Bio typing 
2) Antibiotyping 
3) Serotyping and 
4) Bacteriophage typing. 
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The above methods proved to be of limited value in typing the species in 
comparative studies.
84 
   
Molecular methods of typing:
85-87
 
1) Ribotyping 
2) Pulse field gel electrophoresis.(PFGE) 
3) Restriction enzyme analysis. (REA) 
4) Polymerized chain reaction (PCR) 
 Of the above methods PFGE is considered as the gold standard in 
epidemiological study of enterococcus.
15 
ANTIMICROBIAL RESISTANCE:
 
 Resistance in enterococci is of two types‟ intrinsic/inherent resistance and 
acquired resistance. The intrinsic resistance of these species is chromosomal in 
nature. Resistance to penicillin (low level), cephalosporins, nalidixic acid, 
lincosamides, low level clindamycin and low level aminoglycoside has been 
noted.
4     
1) Resistance to beta lactams: 
Resistance is exhibited by one of the following mechanisms: 
a) Intrinsic resistance to beta lactam antibiotic 
b) Tolerance to beta lactams 
c) Beta lactamase production 
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a) Intrinsic resistance: This property is mainly exhibited due to the low affinity 
of penicillin binding protein PBP-5. In comparison of E.faecalis which has an 
MIC of 1 to 8 µgm/ml to penicillin; E.faecium has higher MIC of about 16-64 
µgm/ml.
4,12
 
b) Tolerance to beta lactams: This is exhibited by the species in being inhibited 
but not killed by the presence of these antimicrobials. Tolerance is shown by 
most of the enterococcal species which justifies the usage of combination drugs 
as cell wall active agents along with aminoglycosides in treatment of serious 
infections rather than using monotherapy.
8  
c) Beta lactamase production: Enterococci producing beta lactamase with 
higher MIC to ampicillin and penicillin have been isolated. The amount of beta 
lactamase produced is little and may go undetected by routine antibiotic 
screening in laboratories. Enterococcal infections from serious infections have to 
be tested for beta lactamase activity. The method recommended for its detection 
is cephalosporin (nitrocefin) impregnated disc. Isolates with this property is 
susceptible only in combination with clavulanic acid, tazobactam and 
sulbactam.
88  
2) Resistance to clindamycin:  
         Studies have been reported in enterococcal resistance against Clindamycin 
and Lincomycin. The MIC of these strain vary from 12.5 to 100µgm/ml.
89 
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3) Resistance to aminoglycosides: 
    Resistance is of two types
4
 
a) Intrinsic resistance. 
b) Acquired resistance.\ 
a) Intrinsic resistance: Enterococcus species have a low level of resistance to 
aminoglycosides intrinsically. The MIC„s range from 8-256µgm/ml. This is 
overcome by the synergy effect by combination of beta lactam antibiotic with an 
aminoglycoside. This effect is mainly useful to treat long standing serious 
infections. 
b) Acquired resistance: Synergistic effect of enterococci was affected when the 
organism developed high level resistance to streptomycin initially.
90
 This HLR 
was subsequently observed to gentamicin and penicillin combination.
91 
                 
The high level resistance is defined when the isolates have an MIC 
>2000µgm/ml for streptomycin and MIC >500µgm/ml for gentamicin. The 
resistance is mainly brought about due to the presence of plasmid mediated 
aminoglycoside modifying enzyme. The most commonly observed enzymes are: 
a) 2‟phosphotransferase and 6‟acetyl transferase observed in all 
aminoglycoside usage except streptomycin. 
b) 3‟ phosphotransferase observed in HLR to penicillin-amikacin synergy 
and kanamycin without gentamycin. 
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c) 6‟ adenyl transferase having HLR to streptomycin only.  The methods 
involved in studying the high level resistance include agar screening, 
broth dilution, high content disc and broth dilution method.
4 
 
4) Resistance to glycopeptides:  
 Resistance to glycopeptides mainly vancomycin was reported in 1988 in 
the UK first.
92  
The peptidoglycan layer of the enterococcus is cross linked with 
the help of a pentapeptide chain at the D-ala ends. Vancomycin sensitive strains 
are attacked at the cross linking stage and its disrupted thus affecting its 
stability.The resistant strains have D-lac at the ends instead of D-ala thus 
overcoming the action of vancomycin and preserving the cross linkage.
93 
Phenotypically the vancomycin resistant strains are classified into 6 types: Van 
A, Van B, Van C, Van D, Van E and Van G. Of these Van A and Van B are 
more commonly associated with E.faecalis and E.faecium.
15  
TABLE.2:
3 
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1) Van A:  This shows high level resistance to both Vancomycin with a MIC of 
>=64µgm/ml and to Teicoplanin with MIC of >=16µgm/ml. Genotypically, van 
A gene is located on the transposon (Tn 1546), which is a part of the plasmid. 
2) Van B: This shows resistance to Vancomycin with MIC of 32 to 64µgm/ml 
but is sensitive to Teicoplanin. The van B gene is situated on the mobile segment 
of the plasmid and is interchangeable between the species. 
3) Van C: This is associated with a low level of resistance to Vancomycin but 
susceptible to Teicoplanin. They are commonly seen in the motile species of 
Enterococcus which includes E.gallinarum and E.casseliflavus. The MIC range 
between 2 to 32µgm/ml. This is intrinsic in nature unlike others which are 
acquired. 
4) Van D: First isolated in a hospital in New York. This strain showed resistance 
to Vancomycin at a MIC of 64µgm/ml and to Teicoplanin at 4µgm/ml. This was 
found in the chromosome and is not associated with the transfer of resistance.
94  
5) Van E: Enterococcus with this gene showed low level of resistance to 
Vancomycin with MIC of 16µgm/ml but sensitive to Teicoplanin with MIC of 
0.5µgm/ml. This phenotype had similarity with Van C.
95  
6) Van G: This shows low level resistance to Vancomycin with a MIC of 
16µgm/ml but sensitive to Teichoplanin.
96 
Studies demonstrate that mutants have emerged that have similarities between 
two phenotypes.
3  
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VANCOMYCIN DEPENDENT ENTEROCOCCI: 
          This includes those species that are not only resistant to Vancomycin but 
require it for its growth. This group of enterococci alters their normal production 
of D-Ala-D-Ala and is able to grow only in the presence of Vancomycin. This is 
due to the production of Van H(dehydrogenase) and ligase(Van A or Van B) that 
forms the D-Ala-D-Lac only if Vancomycin is present. If the Vancomycin is not 
present then there is no D-Ala-D-Lac and without either of these enterococci 
cannot survive. Reversion to Vancomycin independent form is observed which 
is due to mutation.
3 
VANCOMYCIN RESISTANT ENTEROCOCCI (VRE): 
          Vancomycin resistant enterococci (VRE), reported initially in Europe in 
1988, raised a threat to public health. Following this there was an increase in the 
number VRE isolates. They were associated with the raised mortality rates with 
no antimicrobials acting against them.
47 
The VRE rates were found to be more in 
the US than other places. The geographical variation was initially thought due to 
the use of glycopeptide (avoparcin) as a growth promoter in animal feeds. This 
resulted in the cross resistance among the bacteria against vancomycin and 
teicoplanin. The spread of resistance was considered to be originated from 
animal source. But this did not prove to be an explanation for its prevalence in 
the US where the drug avoparcin was not licensed for animal feed.
8 
              Enterococci with acquired vancomycin resistance are a major concern 
in the hospitals. Their importance has also increased due to the spread of its 
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resistance to Staphylococcus. This resistant species has the ability to survive for 
long periods and can spread to patients from health care workers. The infections 
caused by them are related to the immune status of the patient. 
Immunocompetent are not affected whereas the immunocompromised are 
susceptible to life-threatening infections. 
97 
The rate of VRE in India is nearly 
8.7% in which the Van A phenotype is the most common.
98 
COLONISATION AND PATHOGENECITY OF VRE: 
           Studies suggested that there was an increase in the number of patients 
colonized with VRE on screening the rectal swabs from high risk groups.
99 
 The 
main sites affected by VRE include urinary sites, intra-abdominal sites, surgical, 
blood stream and vascular sites. Infections caused by them led to serious 
complications and death due to bacteremia was estimated to be 60- 70%.
100 
Studies have reported that patients with serious conditions and transplant 
recipients are mainly affected by VRE strains.
101 
 
 Blood stream infections observed due to enterococcus are mainly catheter 
associated but other sites have also been reported including cerebral spinal fluid 
following any procedure.
102  
 The risk factors with VRE colonization are:
3
 
1) Serious underlying diseases 
2) Gastrointestinal colonization 
3) Long duration of hospital stay 
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4) Immunosuppression as neutropenia 
5) Patients undergoing intraabdominal or thoracic surgery with indwelling 
catheters. 
6) Renal sufficiency 
7) Usage of broad spectrum antibiotics including aminoglycosides, 
cephalosporins, and imipenem. 
           VRE carriers involve patients in the hospital, nursing faculties and other 
hospital staff. Spread is also observed from inanimate objects including 
thermometers, stethoscope, bed rails, sinks, commodes, ECG wires, intravenous 
fluid pumps and doorknobs. 
SCREENING OF VRE carriers:
103 
           The media used for screening of colonizers of VRE bile –esculin azide 
agar with vancomycin at a concentration of 6µg. This was found to be a good 
sensitive media for VRE isolation. Recently there has been an increase in the 
studies related to screening that led to the development of chromogenic media 
for the rapid diagnosis of the isolates in high risk groups. Studies done on the 
comparison of the screening media proved that the specificity was high for 
chromogenic media. This further had an advantage of differentiating the main 
species of enterococcus.  
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TREATMENT OF VRE INFECTIONS: 
 Treatment of VRE infections is becoming problematic. Vancomycin 
resistant E.faecalis strains are found to have moderate susceptibility to 
ampicillin justifying its usage in the treatment. But if the isolates are E.faecium 
then they exhibit moderate resistance to ampicillin. The isolate is labeled 
ampicillin resistant if its able to grow with a drug concentration of 16µg of 
ampicillin per ml. If the strain isolated is resistant to vacomycin and ampicillin 
then additional testing of MIC should be done. Better results are obtained on 
combination of sulbactam with ampicillin rather than treating with ampicillin 
alone. 
            Chloramphenicol has been found to be effective against many drug 
resistant enterococci in vitro.
3 
Another glycopeptide Teicoplanin has proved its 
efficacy against the strains that possess the Van B phenotype. Studies done on 
animal models with enterococcal endocarditis have proved to be effective when 
combined with an aminoglycoside. 
104 
 
              E.faecium strains with resistance to both vancomycin and ampicillin 
were found to be susceptible to the combination of beta lactam antibiotic and 
glycopeptide. In these strains the MIC of ampicillin is found to be decreased 
when present in conjunction with vancomycin. This occurs as a result of the 
change in the enzyme used by the species for cell wall synthesis. The MIC of 
ampicillin will be reduced if this new enzyme is susceptible to ampicillin. 
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             The identification of drug effective against multiple drug resistant 
enterococci is under trial. Identification of Dalfopristin- quinpristin which is a 
streptogramin antibiotic was successful against vancomycin resistant E.faecium 
in proving its bacteriostatic effect but not active against faecalis.
105  
 
           The introduction of oxazolidones, newer antibiotic had a good 
bacteriostatic effect against enterococcal species. It acts by inhibiting the 
translocation at the initiation of protein synthesis. Studies have proved them to 
be effective against multidrug resistant strains.
106 
CONTROL OF VRE:
 
           Studies have stressed that control of spread of vancomycin resistant 
enterococci plays a crucial role in preventing the spread of infections. These 
include justifiable use of vancomycin in treatment of infections, monitoring high 
risk patients on third generation cephalosporins, educating the hospital staff on 
the importance of infections caused and spread of VRE, effectiveness of the 
laboratory in early identification of carriers by appropriate screening methods 
and implementation of proper infection control programme in all the hospitals.
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Aims and Objectives 
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AIM: 
1. To isolate and speciate  Enterococcus from clinical samples sent to the 
microbiological laboratory. 
OBJECTIVES: 
1. To isolate and speciate  Enterococcus from clinical samples sent to the 
microbiological laboratory 
2. To study the antibiotic susceptibility pattern of the isolates. 
3. To detect beta lactamase production among enterococcal isolates. 
4. To detect the aminoglycoside and Vancomycin resistance among the 
isolates by genotypic methods. 
5. To screen the high risk patients in critical care areas for VRE colonization 
from stool samples.  
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  Materials and methods 
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STUDY POPULATION:  Inpatients and outpatients of PSG Hospitals. 
STUDY LOCALE: Diagnostic Microbiology Laboratory, PSG Hospitals. 
STUDY PERIOD: APRIL 2014 – AUGUST 2015 
SAMPLE SIZE ESTIMATION: 250 isolates 
SAMPLING METHOD: Non- randomized sampling 
INCLUSION CRITERIA: Samples from miscellaneous section, urine section 
and blood section 
EXCLUSION CRITERIA: Samples from respiratory section. 
CONFIDENTIALITY: Confidentiality of the reports were maintained 
TYPE OF STUDY: Observational study 
ETHICAL CLEARANCE: The Institutional Human Ethical clearance was 
obtained before the commencement of the study. Informed consent was obtained 
before collecting the faecal samples for VRE screening. 
 A total of 250 isolates of Enterococci obtained from outpatient and inpatient 
samples from blood section, miscellaneous and urine section were processed for 
the species identification, antimicrobial sensitivity followed by molecular study. 
Specimen processing: Specimens from various sections including urine, pus and 
blood for cultures were collected and processed in the laboratory.  
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FLOW CHART FOR IDENTIFICATION OF ENTEROCOCCUS 
SAMPLES 
(Urine, Miscellaneous, Blood) 
 
                       
  Blood agar                 Mac  Conkey agar 
 
(Alpha/Beta/Gamma haemolysis)     (Tiny lactose fermenter) 
 
 
Stool / Rectal Swab                        Catalase (Negative) 
High risk patients         Gram stain – Gram positive cocci in pairs / short chains 
in ICU / Ward                                        Bio chemical test 
AST 
 
Beta Lactamase                 Kirby Bauer               Automated               Screening
  
Detection                         Disc Diffusion                   Vitek       Agar 
 
                                                                        Resistant Isolates  
      
Chromogenic                                 HLGR                            Vancomycin resistant 
Nitrocefin Disc                                                
                                                                       Molecular Study 
 
Vancomycin Screening Agar 
VRE Carriers Isolated 
 
46 
 
 
PUS/WOUND SWABS: The swabs were streaked in blood agar and 
MacConkey agar and were incubated at 37
0
C for 24 hours.  
URINE: A loopful of the uncentrifuged specimen was examined as a wet mount 
for the presence of pus cells and bacteria. One  loopful of specimen was 
inoculated onto blood agar and Mac Conkey agar. Plates were incubated at 37
0
 C 
for 24 hours.
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1) Growth in Sheep Blood agar: Following overnight incubation of the 
samples, colonies of Enterococcus were seen as grey colonies of about 0.5-1mm 
in diameter with alpha, beta or gamma haemolysis. 
2) Growth in Mac Conkey agar: Colonies were about 0.5- 1mm in size with a 
smooth surface and convex margins, tiny magenta colored following 18-24 hour 
growth. 
3) Catalase test: A drop of the catalase reagent (30% hydrogen peroxide) was 
added to the slide. The growth was further applied to it with an applicator stick. 
Appearance of bubbles was taken as positive test. Enterococcal colonies showed 
a negative test due to the absence of bubbles. 
4) Gram stain: Smears made from the colony showed Gram positive cocci 
arranged singly, in pairs or in short chains. 
STORAGE: If the isolate was catalase negative, gram staining showing the 
presence of gram positive cocci in pairs or short chains and growth in 
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MacConkey agar as tiny lactose fermenting colonies, they were sub cultured and 
pure growth was stocked in Robertson‟s cooked meat medium in tubes. The 
tubes were sealed and stored at 4-8
0
C for 3-6 months. When the test was to be 
done they were further sub cultured. 
IDENTIFICATION TESTS: 
1) Growth in media with pH – 9.6: Isolated colonies of Enterococcus was 
streaked in a media with a pH 9.6 and incubated at 37
0
C overnight. The presence 
of growth was taken as positive. 
2) Tolerance with 6.5%NaCl: The colonies were inoculated in a broth with 
6.5% NaCl, and incubated overnight. The next day the tubes were checked for 
any increase in turbidity. This was further confirmed by sub culturing onto the 
agar plates. Growth confirmed the presence of organism. Whereas absence of 
turbidity indicated organism was unable to grow in this concentration. 
3) Heat tolerance test: Enterococcus was inoculated in Todd-Hewitt broth. It 
was later incubated in water bath set at 45
o
C overnight and 60
0 
C for half an 
hour, and then subcultured. Enterococci survived both the temperature showing 
positive reaction. 
4) Bile aesculin test: Colonies from 24 hour culture were inoculated in media 
containing 40% bile. Blackening of the medium confirmed positive reaction for 
enterococci and non-enterococci. 
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5) PYR test: The colonies were inoculated in PYR broth and incubated for a 
period of 4 hours. Later 3 drops of PYR reagent was added to it and change of 
colour to red was confirmed positive indicating enterococci whereas absence of 
colour change indicates negative test. 
6) Motility test: Stab culture of the colony was done in a semi-solid media and 
motility was indicated by the spread of the organism into the media. The strains 
which did not diffuse into the media were considered non motile. Tubes were 
incubated for up to 7 days for confirming motility.  
7) Arginine test: A well isolated colony of Enterococcus from the culture was 
inoculated in Moeller‟s decarboxylase media with arginine as the amino acid and 
overlaid with mineral oil. After 24 hours of incubation the colour of the tube was 
changed to purple indicating a positive reaction. Yellow colour indicated only 
acid production only and no deamination. 
8) Potassium tellurite reduction test: Colonies were streaked in media 
containing 0.004%potassium tellurite. E.faecalis formed black colonies with the 
reduction of tellurite to tellurium. This test was used to differentiate E. faecalis 
from E.faecium. 
9) Pyruvate test: When inoculated in a media containing pyruvate with 
bromothymol blue as indicator E.faecalis showed a colour change from green to 
yellow color after overnight incubation. Absence of colour change ruled out 
E.faecalis. 
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10) Pigment production: Ability to produce pigment was observed by a few 
species of enterococci. This was tested by sub culturing colonies in nutrient agar. 
Any color produced was visible and also further confirmed by touching the 
colony with a sterile swab. 
11) Sugar fermentation tests: Species identification was further done by sugar 
utilization by inoculating the organism in peptone with 1% sugars with Andrade 
indicator. The sugars used were mannitol, arabinose, raffinose, sorbose, sorbitol, 
lactose and sucrose. Any change in colour from colourless to pink indicated the 
positive sugar fermentation test. Absence of colour change was taken as 
negative. 
ANTIMICROBIAL SUSCEPTIBILITY TEST:
77 
 
The 250 test isolates of Enterococci were checked for the antimicrobial 
susceptibility pattern using Kirby-Bauer disc diffusion method. Three or four 
pure colonies were inoculated in peptone water and incubated for about 3 hours. 
The turbidity of the growth was matched to 1 of Mc Farlands. A lawn culture of 
the broth with a sterile swab was done in Muller Hinton agar and the discs were 
placed at a distance of 24 mm. About 6 discs were kept on each plate. The discs 
used were Penicillin (10U), Ampicillin (10µgm), Amoxicillin Clavulanic acid 
(20/10), Erythromycin (15µgm), Vancomycin(30µgm), High level 
gentamicin(120µgm), Linezolid(30µgm), Tetracycline(30µgm). For isolates 
from urine section Norfloxacin (10µgm) and Nitrofurantoin (300µgm) was kept. 
All discs were bought from HIMEDIA.   
 
50 
 
         Zones of inhibition were measured and recorded and the organism was 
interpreted as sensitive or resistant as per the recommendations from CLSI 
guidelines. 
ANTIBIOTIC 
DISC 
CONTENT 
(µgm) 
RESISTANT 
(mm) 
INTERMEDIATE 
(mm) 
SUSCEPTIBLE 
(mm) 
Penicillin 10 U 14 - 15 
Ampicillin 10 16 - 17 
Amoxycillin 
Clavulanic 
acid 
20/10 16 - 17 
Erythromycin 15 13 - 23 
Vancomycin 30 14 15-16 17 
High level 
gentamicin 
120 6 7-9 10 
Linezolid 30 20 21-22 23 
Norfloxacin 10 12 13-16 17 
Nitrofurantoin 300 14 15-16 17 
Tetracycline 30 14 15-18 19 
 
Quality Control: Enterococcus faecalis ATCC 29212 was used. 
 SCREENING FOR HIGH LEVEL GENTAMICIN RESISTANCE:
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         Screening media for high level gentamicin resistance was prepared. 
Screening for high level gentamicin resistance was done by agar dilution 
method. BHI agar with gentamicin at a concentration of 500µgm/ml was added 
and the plates were prepared. Inoculum of 10µL of 0.5 Mc Farland was spot 
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inoculated. Presence of even 1 colony was interpreted as a resistant strain. These 
strains were collected for molecular studies. 
AUTOMATED INSTRUMENT SYSTEM FOR IDENTIFICATION & 
ANTIBIOTIC SENSITIVITY (VITEK 2 COMPACT SYSTEM): 
 Samples were prepared and loaded into the system as per the 
manufacturer‟s instructions. About 3-4 fresh and pure isolated colonies from the 
blood agar plate was taken and mixed with 280µl of saline and the turbidity was 
matched to 0.5-0.63 of Mc Farland . The samples were placed in the plastic 
reagent cassette provided and loaded into the Vitek machine. After a period of 8-
10 hours, identification and sensitivity report of the isolate was collected.  
 Fifty isolates of Enterococci obtained by conventional biochemical 
speciation were compared with the automated method (Vitek 2 system).   
 The Minimum inhibitory concentration of high level gentamicin resistant 
strains by the automated system for 50 isolates for which genetic study was to be 
carried out was noted. Similarly the Minimum inhibitory concentration of six 
isolates with vancomycin resistance by automated system was noted to detect the 
presence of vanA gene. 
DETECTION OF BETA LACTAMASE: 
4
 
 The detection of beta lactamase test was done based on the chromogenic 
cephalosporin method. Nitrocefin disc was obtained commercially from BD. The 
disc was moistened with sterile saline and pure isolated colony was applied on it. 
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The reaction was read within 5 min. Isolates producing beta lactamase produced 
a red colour. 
SCREENING FOR VRE FROM STOOL SAMPLES:  
 Screening of 100 high risk patients in the hospital Intensive Care Unit 
was done to identify the VRE carriers. Informed consent from the patients 
relatives was obtained. Rectal swabs were collected and streaked in the 
chromogenic VRE Chrom ID media obtained from BIOUMERIUX. The colour 
of the colonies was observed after a period of 48 hours of incubation. The 
presence of violet colour colonies indicated E.faecium and blue colour colonies 
indicated E.faecalis. Isolates with intrinsic resistance and most of the other gram 
positive organisms were selectively inhibited by the media. 
MOLECULAR STUDY OF ISOLATES: 
 Fifty isolates of enterococcus with resistance to high level gentamicin 
both by disc diffusion and by automated Vitek 2 system were studied 
genetically. 
 Similarly six vancomycin resistant isolates obtained were genetically 
analysed. 
 The colonies grown in blood agar plate were inoculated in 5ml of BHI 
broth and incubated for 24 hours at 37
0
C. 
 They were centrifuged at 2000rpm for 10 minutes. 
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 Supernatant was discarded by pipetting and the pellet was used for DNA 
extraction. 
DNA EXTRACTION: 
         The DNA was extracted using the QIAGEN kit. The procedure was done 
based as per the manufacturer‟s instruction. 
Pre-extraction steps: 
 Absolute ethanol of about 25 ml was added to wash buffer 1(AW 1) 
 Next, absolute ethanol measuring 25 ml was added to buffer 2(AW 2) 
 The dry bath was set at 560 C. 
Extraction step: 
 Proteinase K measuring 20µl was added to a clean tube of about 1.5 ml 
capacity. 
 About 200µl sample was added to the previous tube. 
 The contents were vortexed after adding 200µl of lysis buffer. 
 The contents were incubated at 560C for 10 minutes. 
 The lysate obtained was then transferred to upper reservoir of the spin 
column tube. 
 It was centrifuged at 8000rpm for 1 minute again. 
 The column was once again transferred to a new 2ml collection tube and 
filtered. 
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 Nearly 500µl of AW1 (wash buffer 1) was added and centrifuged at 
800rpm for 1 min. 
 The spin column tube was then transferred to a new 2ml collection tube 
and filtered. 
 Nearly 500µl of AW2(wash buffer 2) was added and centrifuged at 
14000rpm for 3 min and at 14800rpm for 1minute. 
 After filtration, the spin column was shifted to 1.5ml tube. 
 About 210µl of elution buffer was added and kept at room temperature 
for 5 minutes. 
 It was then centrifuged at 8000rpm for 1 minute. 
 The final eluted DNA was collected in tube of 1.5 ml capacity. 
Storage of the DNA: The eluted DNA was stored at -20
0
C. 
PCR: The presence of bifunctional gene for HLGR and van A gene for 
vancomycin resistance was detected by doing PCR and bands observed under 
UV illumination. 
DETECTION OF aac(6’) le aph(2”) la gene : 
         The primers for HLGR with a base pair of 348 bp were amplified. The 
sequence was obtained from the studies done previously
109
. PCR Master mix: 
The master mix was prepared as follows: 2.5µl of PCR buffer,2.5µl of MgCl2, 
2.5µl of DNTPs, 10.2µl of Mili Q H2O, 1µl of forward and reverse primers and 
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0.3µl of Taq Polymerase was added to eppendoff. From the above mixture 18µl 
was taken and 5µl of the extracted DNA was added.  
Primers for aac(6‟)Ie- aph(2”)la with base pair of 348 bp109: 
F (5‟CAGAGCCTTGGGAAGATGAAG3‟) 
R (5‟CCTCGTGTAATTCATGTTCTGGC3‟) 
PCR Program: The program consisted of initial denaturation step at 95
0
C for 
10 minutes followed by 30 cycles of denaturation at 94
0
C for 300 seconds, 
annealing  at 56
0
C for 1 minute and extension at 72
0
C for a period of 1 minute. 
The program had a holding temperature of 72
0
C for 10 minutes. 
ANALYSIS: PCR products were analyzed by running gel electrophoresis with 
1.5% agarose gel in Tris Boric acid buffer. The samples along with the controls 
obtained by running ladder were analysed.The gel was stained with ethidium 
bromide and the bands were obtained were visualized under UV light and also in 
automated GEL DOC viewer. 
DETECTION OF vanA gene: 
         The primers with a base pair of 732bp for detection of vanA  were obtained 
from the studies done previously. 
Primers for van A with base pair of 732bp
110
:  
F (5‟ GGGAAAACGACAATTGC-3‟) 
R (5‟GTACAATGCGGCCGTCGTTA-3‟) 
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PCR Program: This program had a denaturation step at 95
0
C for 5 minutes 
followed by 30 cycles of DNA denaturation at 95
0
C for 1 minute, annealing at 
54
0
C for 45 seconds and primer extension at 72
0
C for 45 seconds. This was 
followed by a holding temperature of 72
0
C for 10 minutes. 
ANALYSIS: PCR products were analyzed by running gel electrophoresis with 
1.5% agarose gel in Tris Boric acid buffer. The samples along with the controls 
obtained by running ladder were analysed.The gel was stained with ethidium 
bromide and the bands were obtained were visualized under UV light and in 
automated GEL DOC viewer. 
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         Results 
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All the 250 isolates of enterococcus from various clinical samples including 
urine, pus, wound swab, blood and CSF were processed.  
 Gram stain showed 100% for the presence of gram positive cocci in pairs 
and short chains. (Illustration 1) and produced tiny lactose fermenting 
colonies on MacConkey media. (Illustration 2). 
 Illustration 3 shows the storage media used to preserve enterococcal 
isolates. 
 Figure 1 depicts the distribution of enterococcal species among the various 
samples received. Out of 250 samples, 184(73.6% ) were from urine 
section, 14(5.6% ) from blood section, 4(1.6% ) from peritoneal samples 
and  bile, 1 (0.4% ) from CSF and 24(9.6% ) from wound samples. 
 Table 1 shows the percentage of enterococcus obtained as pure and mixed 
cultures. Majority of the isolates were obtained as pure growth which 
accounted for about 216(86.4%) and 34(13.6%) was obtained as mixed. 
Among the mixed, incidence of other organisms were in the order 
Escherichia coli was 20(58.8%), Klebsiella pneumonia 7(20.5% ), 
Pseudomonas aeruginosa 2(5.88% ), Enterobacter species 3(8.82% ) and 
Candida species 2(5.88% ). 
 Figure 2 depicts the speciation of enterococcal isolates. Out of the 250 
isolates, 157(62.8%) were E.faecalis, 79(31.6% ) were E.faecium, 5(2%) 
were E.durans,7( 2.8%) were E.raffinosus and 2(0.8%) were E.caseliflavus. 
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 Illustration 4 shows the genus specific biochemical tests used in 
identification. 
 Table 2 depicts the various biochemical tests used in speciation of 
enterococcus. 
 Figure 3 shows the comparison of the manual biochemical tests with the 
automated Vitek system in the identification of enterococcus. 
 Illustration 5 shows the series of biochemical tests used in the speciation. 
 Table 3 depicts the antibiotic susceptibility pattern of enterococcal isolates 
by disc diffusion method. Out of 250 isolates ampicillin sensitive strains 
were 173(69.2%  ), HLG sensitive strains were 123 (49.2% ), erythromycin 
sensitivity was observed in 59 (89.3% ), vancomycin sensitive were 243 
(97.2% ), teicopanin sensitive were 188 (75.2%).For urinary isolates, 
norfloxacin sensitivity was 83.15%  and 170(92.39% ) strains were 
sensitive to nitrofurantoin. 
 The maximum sensitivity was observed for linezolid followed by 
vancomycin, teicoplanin, ampicillin and high level gentamicin. Among the 
urinary isolates nitrofurantoin was observed to be sensitive in majority of 
the strains followed by norfloxacin and then tetracycline. Non urinary 
isolates had maximum sensitivity to erythromycin. 
 Illustration 6 shows the Kirby Bauer‟s disc diffusion test done for 
antibiotic susceptibility. 
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 Figure 4 shows the screening of VRE carriers among the high risk patients. 
Out of 100 patients screened, 3% were identified as carriers. 
 Figure 5 depicts the comparison of resistance pattern obtained by disc 
diffusion, HLGR (high level gentamicin resistance) screening agar and 
Vitek in identifying resistant strains. 
 Illustration 7 shows the high level gentamicin screening agar used to 
identify the resistant strains. 
 Table 4 depicts the number of isolates exhibiting beta lactamase property. 
None of the isolates were positive for beta lactamase by chromogenic 
method. 
 Illustration 8 shows the chromogenic nitrocefin disc used to screen the 
presence of beta lactamase  
 Illustration 9 shows the chromogenic VRE screening agar used for the 
identification of carriers. 
 Figure 6 depicts the presence of bifunctional gene aac (6‟)le aph(2”) la in 
high level gentamicin resistant strains. Out of the 50 randomly selected 
resistant strains for genotype study 48(96%) had the gene. 
 Illustration 10 shows the presence of bands of size 348 bp in the isolates 
confirming the gene. 
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 Figure 7 shows the presence of vancomycin resistant isolates. Out of 250 
isolates 7 (2.8%) were resistant to vancomycin with 5 strains positive for 
van A gene. 
 Illustration 11 shows the presence of van A gene of base pair 732 
confirming the presence of gene. 
62 
 
TABLE 1: COMBINATIONS OF ENTEROCOCCI OBTAINED AS PURE 
AND MIXED CULTURES                                                                      
N=250 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No. Bacteria 
Percentage of 
isolates 
1 Pure Enterococcal isolates 86.4 
2 Enterococci with Escherichiae coli 58.8 
3 
Enterococci with Klebsiella 
pneumoniae 
20.5 
4 
Enterococci with Pseudomonas 
aeruginosa 
5.88 
5 
Enterococci with Enterobacter 
species 
8.82 
6 Enterococci with Candida albicans 5.88 
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TABLE 2: BIOCHEMICAL TESTS FOR ENTEROCOCCUS SPECIES 
IDENTIFICATION 
S. 
No 
No of 
isolates N 
= 250 
1                                   
N = 157 
2                               
N = 79 
3                                   
N = 5 
4                         
N = 7 
5                        
N = 2 
  
P N % P N % P N % P N % P N % 
1 Mannitol 157 0 100 79 0 100 0 5 0 7 0 100 2 0 100 
2 Motility 0 157 0 0 79 0 0 5 0 0 7 0 2 0 100 
3 Sucrose 0 157 0 0 79 0 2 3 40 1 6 14.2 0 2 0 
4 Arabinose 0 157 0 79 0 79 1 4 20 5 1 71.4 2 0 100 
5 Raffinose 0 157 0 50 29 63.2 5 0 100 7 0 100 2 0 100 
6 Sorbitol 150 7 95.5 11 68 13.9 0 5 0 7 0 100 2 0 100 
7 Sorbose 0 157 0 0 79 0 0 5 0 7 0 100 1 1 50 
8 Arginine 157 0 100 79 0 100 5 0 100 0 7 0 2 0 100 
9 
Potassium 
tellurite 
(0.4 
grams) 
157 0 100 0 79 0 0 5 0 0 7 0 0 2 0 
10 Pyruvate 140 17 89.1 0 79 0 3 2 60 3 4 42.8 0 2 0 
11 Pigment 0 157 0 0 79 0 0 5 0 0 7 0 2 0 100 
 
1-E.faecalis,   2-E.faecium, 3-E.durans, 4-E.raffinosus, 5-E.casseliflavus 
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TABLE 3: ANTIBIOTIC SUSCEPTIBILITY PATTERN OF 
ENTEROCOCCAL ISOLATES 
                                                                                            N = 250 
 
ANTIBIOTICS SENSITIVE RESISTANCE 
AMPICILLIN 173 77 
% 69.2 30.8 
HIGH LEVEL 
GENTAMICIN 
123 127 
% 49.2 50.8 
VANCOMYCIN 243 7 
% 97.2 2.8 
LINEZOLID 247 3 
% 98.8 1.2 
TEICOPLANIN 188 62 
% 75.2 24.8 
 
 
FOR URINARY ISOLATES      N = 184 
 
ANTIBIOTICS SENSITIVE RESISTANCE 
NORFLOX 153 31 
% 83.15 16.85 
NITROFURANTOIN 170 14 
% 92.39 7.61 
TETRACYCLINE 147 37 
% 79.89 20.11 
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FOR NON - URINARY ISOLATES    N = 66 
 
ANTIBIOTICS SENSITIVE RESISTANCE 
PENICILLIN 17 49 
% 25.75 74.25 
ERYTHROMYCIN 59 7 
% 89.3 10.7 
 
 
TABLE 4: SCREENING FOR BETA LACTAMASE ACTIVITY BY 
NITROCEFIN DISC 
N = 100 
 
 
 
 
 
 
 
 
 
 
 
 
N = 100 
POSITIVE NEGATIVE 
0 100 
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Figure 1 – Distribution of Enterococcus isolates among various samples 
(N=250) 
 
 
 
 
 
 
 
 
 
Figure 2 – Speciation of Enterococcus from Clinical Isolates 
N=250 
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Figure 3 – Comparison of Enterococcus Species Identification 
N=50 
 
  
 
 
 
 
 
 
 
 
 
Figure 4 – Screening of VRE carries from Stool 
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Figure 5 – Comparison of Detection of resistant HLGR enterococcus 
N=50 
 
 
 
 
 
 
 
 
 
Figure 6 – Detection of the presence of aac (6’) le aph (2”) la gene 
N = 50 
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Figure 7 – Detection of van A gene among the VRE isolates (N=7) 
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IILUSTRATION 1: GRAM STAIN 
 
 
 
 
 
 
 
 
ILLUSTRATION 2:  Mac Conkey Agar plate 
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ILLUSTRATION 3:  ROBERTSON COOKED MEAT (RCM) MEDIA 
 
 
 
 
 
 
 
 
 
 
ILLUSTRATION 4: GENUS SPECIFIC TEST 
A) BILE-ESCULIN TEST                                                       B) PYR TEST 
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C) 6.5% NaCl test: 
 
ILLUSTRATION 5: SPECIES SPECIFIC TEST 
A) Enterococcus faecalis:                                         B) Enterococcus  faecium: 
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ILLUSTRATION 6: KIRBY- BAUER DISC DIFFUSION TEST 
 
ILLUSTRATION 7.A: HIGH LEVEL GENTAMICIN SCREEN AGAR 
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ILLUSTRATION 7.B: HIGH LEVEL GENTAMICIN RESISTANT 
STRAINS 
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ILLUSTRATION 8: BETA LACTAMASE DETECTION BY 
NITROCEFIN DISC 
 
ILLUSTRATION 9: VRE SCREEN AGAR 
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ILLUSTRATION 10: PCR showing aac(6’)-aph(2”) BAND OF SIZE 348 bp 
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ILLUSTRATION 11: PCR showing van A gene of band size 732bp  
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ILLUSTRATION 12: MATERIALS REQUIRED FOR MOLECULAR 
STUDY 
GEL ELECTROPHORESIS 
  
 
                               
 
 
 
 
 
 
GEL DOC FOR BAND VISUALIZATION 
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Discussion 
        DISCUSSION 
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  Enterococcus has been noted to cause a majority of  urinary tract 
infections. This being the most common followed by bacteremia, sepsis and 
even case reports of meningitis has been reported. In our study out of 250 
samples studied the majority of the isolates were obtained from urinary tract 
infections (73.6%) followed by wound swabs (9.6%) and blood (5.6%).This 
correlates well with other studies in which Enterococci was obtained from urine 
isolates maximally.
111,112 
According to the studies  Enterococci are considered as 
the commonest urinary pathogen justifying the increase in the rate of isolation 
from urinary samples.
8
 
 Among the various species, in our study E.faecalis was the most common 
isolate accounting for 62.8% followed by E.faecium ( 31.6% ), E.durans(2%), 
E.raffinosus(2.8%) and 0.8% E.casseliflavus. Such findings were reported from 
other studies done in Bangalore in which E.faecalis was 59%, E.faecium was 
38% .
113
 
 Identification of the enterococcal isolates by conventional methods and 
automated Vitek 2 Compact system was done which showed a sensitivity and 
specificity of 100% and 90% respectively. Studies done in a similar manner in 
comparison of manual and automated system (Phoenix)in identification of 
isolates showed 94.8% acceptibitity.
114 
Another study done in Greece reported 
that there was no significant difference in the identification of the isolates by the 
two automated systems Vitek 2 and Phoenix.
115
 
81 
 
 Enterococci show intrinsic resistance to cotrimoxazole, clindamycin, 
cephalosporins and normal aminoglycosides. Thus these antibiotics are not 
tested .
77
 
 The antibiotic susceptibility pattern of the isolates in our study showed 
the following:  
 The sensitivity to linezolid was maximum (98.8%) followed by 
vancomycin (97.2%), erythromycin (89.3%), teicoplanin (75.2%), ampicillin 
(69.2%), high level gentamicin (49.2%) and penicillin(25%). Among the urinary 
isolates maximum sensitivity was noted in Nitrofurantoin (92.3%) followed by 
Norfloxacin (83.15%). Studies done in North India showed a similar 
susceptibility pattern with increased resistance to penicillin and 
aminoglycosides. Also the sensitivity percentage to linezolid and vancomycin 
was higher compared to other antibiotics.
116
Another study showed the 
percentage of high level gentamicin resistance to be 68%.
117
 Reports from South 
India showed the resistance percentage of high level aminoglycoside to be more 
than 50%.
118
 
 The screening of vancomycin resistant enterococci (VRE) carriers was 
done in 100 high risk patients in the intensive care units and immunosuppresed 
patients who were found to have a prolonged stay in the hospital. The incidence 
of VRE carriage was found to be 3%. In a similar study done elsewhere carrier 
rate was reported to be  6.6%.
119 
Among the three patients identified as carriers,  
nephropathy  followed by prolonged hospital stay and long term treatment with 
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antibiotics and diabetes was observed as the primary risk factors.
 
The VRE 
carriers identified were isolated and appropriate precautions were advised in 
handling them. The resistant strains were identified to be E.faecium which 
correlated well with other studies that showed 100% of the carriers to colonise 
E.faecium.
120   
  
 The chromogenic media used for the identification of carriers was 
reported to be more specific and convenient than the conventional biochemicals 
in the identification of resistant strains.VRE have been reported to cause serious 
nosocomial infections resulting in mortality and increase in the length of stay in 
the hospital. Rapid identification of these strains helps in early and appropriate 
management .
119 
 
Comparison of screening of resistant strains to high level gentamicin was 
done by disc diffusion, screen agar and Vitek 2 compact which showed a 
sensitivity and specificity of 100%. Similar comparative study showed 99% 
correlation. 
121
 High level gentamicin screen agar is comparatively cheaper and 
more efficient than disc diffusion and automated Vitek 2 system in identifying 
resistance. This method also has the advantage of testing many strains on a 
single agar plate. As there is an increase in the resistance rate exhibited by the 
isolates susceptibility to synergistic combinations with beta lactams is not 
effective in such isolates. 
8
 This could be used as a screening method in low cost 
settings where facilities like Vitek are not available. 
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         The detection of beta lactamase production by the chromogenic nitrocefin 
disc method showed that none of the isolates had beta lactamase enzyme. 
Studies done in Delhi and in Maharashtra also showed similar results.
122,123 
The 
resistance to beta lactams though common, the mechanism could be due to 
alteration in penicillin binding protein PBP 5 which is more common than beta 
lactamase production. 
88
 
 The molecular study done to detect the presence of the resistant gene 
confirmed the presence of the bifunctional gene aac (6‟)le-aph (2”)la of base pair 
348 to be present in 48(96%) out of the 50 randomly selected resistant strains. 
Studies done in Chennai have showed the presence of this gene in 38.2% of the 
isolates
124
 whereas there are other studies in which all the resistant isolates 
possessed this bifunctional gene.
125
The resistance to high level gentamicin 
indicates resistance to all the aminoglycosides except streptomycin. 
77 
The 
combination effect of aminoglycoside with beta lactam antibiotic is not helpful 
in the treatment of patients possessing such resistant strains. 
        Out of the 250 isolates the vancomycin resistant isolates obtained in our 
study was 2.8%. Studies have shown the prevalence of vancomycin resistance to 
be less in India ranging around 1.7-20%.
118
 
       Molecular studies revealed the presence of van A gene in 5(71.42 %) 
isolates.. Studies have also been reported showing van A to be the most common 
genotype isolated among the vancomycin resistant strains.
98 
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Out of the seven isolates, five were E.faecium and two were E.casseliflavus. 
The remaining two isolates were E.casseliflavus which would have exhibited 
intrinsic resistance to vancomycin with van C gene.
98  
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                         Summary & Conclusion 
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During the study period between April 2014-August 2015, out of the 250 
isolates studied, 
1) The incidence of enterococci from the clinical isolates in our study was 
2.5%. 
2) The incidence of the pure isolates was 86.4% in comparison to the mixed 
isolates which was found to be 13.6%. 
3) Among the isolates of enterococci, the predominant species was 
E.faecalis(62.8%) followed by E.faecium(31.6%), E.raffinosus(2.8%), 
E.durans(2%) and  E.casseliflavus( 0.8%). 
4) The antibiotic sensitivity pattern of the urinary isolates showed 92.3% 
sensitive to nitrofurantoin and  83.15% sensitive to norfloxacin. Among 
the non-urinary isolates maximum sensitivity was observed in linezolid 
which was 98.8% followed by vancomycin (97.2%), erythromycin 
(89.3%), teicoplanin (75.2%), ampicillin(69.2),  high level gentamicin 
sensitivity( HLG) (49.2%) and  pencillin (25%). 
5) Comparison of screening of resistant strains to high level gentamicin was 
done by disc diffusion, screen agar and Vitek 2 compact which showed 
that all the methods had equal sensitivity(100%) and specificity(100%) 
6)  The vancomycin resistance was found to be 2.8% in E.faecium. 
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7) All the isolates were found to  be beta lactamase negative by chromogenic 
(nitrocefin) method proving the alteration in PBP5 to be the more 
common mechanism involved in penicillin resistance. 
8) The molecular characterization of  randomly selected 50 isolates ( out of 
127) of HLGR (high level gentamicin resistant) strains  revealed the 
presence of bifunctional gene(aac (6‟)le-aph (2”) la to be 96%                                                                                         
(Primers of base pair 348 - F (5‟CAGAGCCTTGGGAAGATGAAG3‟) 
                                                      R (5‟CCTCGTGTAATTCATGTTCTGGC3‟) 
9) The presence of van A gene was found to be 71.42% in our study. 
10)  Vancomycin resistant enterococcal( VRE) carrier rate was found to be 
3% in this study. 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bibliography 
1. Murray, Barbara E. "The life and times of the Enterococcus." Clinical 
microbiology reviews 3, no. 1 (1990): 46-65. 
2. Lancefield, Rebecca C. "A serological differentiation of human and other 
groups of hemolytic streptococci." The Journal of experimental medicine 57, 
no. 4 (1933): 571-595. 
3. Cetinkaya, Yesim, Pamela Falk, and C. Glen Mayhall. "Vancomycin-resistant 
enterococci." Clinical microbiology reviews 13, no. 4 (2000): 686-707. 
4. Marothi, Y. A., H. Agnihotri, and D. Dubey. "Enterococcal resistance-an 
overview." Indian journal of medical microbiology 23, no. 4 (2005): 214. 
5. Fisher, Katie, and Carol Phillips. "The ecology, epidemiology and virulence 
of Enterococcus." Microbiology 155, no. 6 (2009): 1749-1757. 
6. Kühn, Inger, Aina Iversen, Lars G. Burman, Barbro Olsson-Liljequist, Anders 
Franklin, Maria Finn, Frank Aarestrup et al. "Comparison of enterococcal 
populations in animals, humans, and the environment-a European 
study."International journal of food microbiology 88, no. 2 (2003): 133-145. 
7. Edward DD. Enterococci attract attention of concerned microbiologist. ASM 
news 2000;66:540:5. 
8. Sood, Seema, Meenakshi Malhotra, B. K. Das, and Arti Kapil. "Enterococcal 
infections & antimicrobial resistance." Indian J Med Res 128, no. 2 (2008): 
111-21. 
9. Saxena, Sonal, S. Krishna Prakash, V. K. Malik, and M. D. Mathur. 
"Vancomycin resistant Enterococcus in nosocomial urinary tract 
infections."Indian journal of pathology & microbiology 46, no. 2 (2003): 
256. 
10. Gordon, Steven, Jana M. Swenson, B. C. Hill, N. E. Pigott, R. R. Facklam, R. 
C. Cooksey, C. Thornsberry, W. R. Jarvis, and F. C. Tenover. "Antimicrobial 
susceptibility patterns of common and unusual species of enterococci causing 
infections in the United States. Enterococcal Study Group." Journal of 
clinical microbiology 30, no. 9 (1992): 2373-2378. 
11. Mendiratta, D. K., H. Kaur, V. Deotale, D. C. Thamke, R. Narang, and P. 
Narang. "Status of high level aminoglycoside resistant Enterococcus faecium 
and Enterococcus faecalis in a rural hospital of central India." Indian journal 
of medical microbiology 26, no. 4 (2008): 369. 
12. Rahangdale, V. A., G. Agrawal, and S. V. Jalgaonkar. "Study of 
antimicrobial resistance in enterococci." Indian journal of medical 
microbiology 26, no. 3 (2008): 285. 
13. Gold, Howard S., and Robert C. Moellering Jr. "Antimicrobial-drug 
resistance."New England Journal of Medicine 335, no. 19 (1996): 1445-
1453. 
14. Andrews FW,Horder TJ.A study of the streptococci pathogenic for man. 
Lancet 1906: 708-713. 
15. Facklam, R. R., L. M. Teixeira, L. Collier, A. Balows, M. Sussman, and A. 
EDWARD. "Topley & Wilson's Microbiology and microbial infections. 
Systemic Bacteriology .10
th
 edition. Vol 2. Newyork, USA: Arnold; 2005 
p.882-902. 
16. Sherman, James M. "The streptococci." Bacteriological reviews 1, no. 1 
(1937): 3. 
17. Facklam, Richard R. "Recognition of group D streptococcal species of 
human origin by biochemical and physiological tests." Applied 
microbiology 23, no. 6 (1972): 1131-1139. 
18. Facklam, R. R., and M. D. Collins. "Identification of Enterococcus species 
isolated from human infections by a conventional test scheme." Journal of 
clinical microbiology 27, no. 4 (1989): 731-734. 
19. Deibel RH. The group D Streotococci.Bacteriol Rev 1964 Sept ; 28(3): 330-
66. 
20. Collins, M. D., D. Jones, J. A. E. Farrow, R. Kilpper-Balz, and K. H. 
Schleifer. "Enterococcus avium nom. rev., comb. nov.; E. casseliflavus nom. 
rev., comb. nov.; E. durans nom. rev., comb. nov.; E. gallinarum comb. nov.; 
and E. malodoratus sp. nov." International journal of systematic 
bacteriology 34, no. 2 (1984): 220-223. 
21. Knight, Royce g., and David m. Shlaes. "Deoxyribonucleic acid relatedness 
of Enterococcus hirae and “Streptococcus durans” homology group 
II." International journal of systematic bacteriology 36, no. 1 (1986): 111-
113. 
22. Ennahar, Saïd, and Yimin Cai. "Biochemical and genetic evidence for the 
transfer of Enterococcus solitarius Collins et al. 1989 to the genus 
Tetragenococcus as Tetragenococcus solitarius comb. nov." International 
journal of systematic and evolutionary microbiology 55, no. 2 (2005): 589-
592. 
23. Teixeira, Lucia M., M. G. Carvalho, M. M. Espinola, Arnold G. Steigerwalt, 
Michael P. Douglas, Don J. Brenner, and Richard R. Facklam. "Enterococcus 
porcinus sp. nov. and Enterococcus ratti sp. nov., associated with enteric 
disorders in animals." International journal of systematic and evolutionary 
microbiology 51, no. 5 (2001): 1737-1743. 
24. Tyrrell, Gregory J., LeeAnn Turnbull, Lúcia M. Teixeira, Johanne Lefebvre, 
S. Carvalho Maria da Glória, Richard R. Facklam, and Marguerite Lovgren. 
"Enterococcus gilvus sp. nov. and Enterococcus pallens sp. nov. isolated 
from human clinical specimens." Journal of clinical microbiology 40, no. 4 
(2002): 1140-1145. 
25. Law-Brown, Janette, and Paul R. Meyers. "Enterococcus phoeniculicola sp. 
nov., a novel member of the enterococci isolated from the uropygial gland of 
the Red-billed Woodhoopoe, Phoeniculus purpureus." International journal 
of systematic and evolutionary microbiology 53, no. 3 (2003): 683-685. 
26. Allen, Stephen D., W. M. Janda, P. C. Schreckenberger, and W. C. Winn.The 
Gram positive cocci.Part 2: Streptococci, Enterococci and the “”Streptococci 
like” bacteria ; Colour Atlas and textbook of Diagnostic microbiology.6th 
edition,Philadelphia ,USA; JC Lippincott, Williams and Wilkins; 2006p.672-
764. 
27. Fisher, Katie, and Carol Phillips. "The ecology, epidemiology and virulence 
of Enterococcus." Microbiology 155, no. 6 (2009): 1749-1757. 
28. Benno, Yoshimi, Kunio Suzuki, Kunihiko Suzuki, Kimiko Narisawa, W. 
Robert Bruce, and Tomotari Mitsuoka. "Comparison of the fecal microflora 
in rural Japanese and urban Canadians." Microbiology and immunology 30, 
no. 6 (1986): 521-532. 
29. Holt JG, Kreig NR, Sneath PHA, Staley JT, Williams ST. Gram positive 
cocci. In Bergey’s manual of determinative bacteriology.9th 
edition.USA:William & Wilkins; 1994.p527-58. 
30. Ross PW.Streptococcus and Enterococcus In: Collee JG, Fraser BP, 
Marmion BP,Simmon A. Mackie an Mc Cartney practical medical 
microbiology.14
th
 edition.USA: Churchill Livingstone;1996.p263-74. 
31. Qadri, SaM, CHARLES W. Nichols, and S. G. Qadri. "Rapid sodium 
chloride tolerance test for presumptive identification of enterococci." Journal 
of clinical microbiology 7, no. 2 (1978): 238. 
32. You, M. S., and R. R. Facklam. "New test system for identification of 
Aerococcus, Enterococcus, and Streptococcus species." Journal of clinical 
microbiology 24, no. 4 (1986): 607-611. 
33. Chuard, C., and L. B. Reller. "Bile-esculin test for presumptive identification 
of enterococci and streptococci: effects of bile concentration, inoculation 
technique, and incubation time." Journal of clinical microbiology 36, no. 4 
(1998): 1135-1136. 
34. Winn W, Allen S, Janda W, Koneman E, Procop G, Schreckenberger 
P,Woods. Colour Atlas and Textbook of Diagnostic Microbiology. 6
th
 
edition. Philadelphia, USA.Lippincott, Williams & Wilkins; 2006.p1442-
1535. 
35. Fertally, S. S., and R. I. C. H. A. R. D. Facklam. "Comparison of physiologic 
tests used to identify non-beta-hemolytic aerococci, enterococci, and 
streptococci." Journal of clinical microbiology 25, no. 10 (1987): 1845-1850. 
36. Appelbaum, PETER C., P. S. Chaurushiya, M. R. Jacobs, and A. Duffett. 
"Evaluation of the rapid strep system for species identification of 
streptococci."Journal of clinical microbiology 19, no. 5 (1984): 588-591. 
37. Appelbaum, P. C., M. R. Jacobs, J. I. Heald, W. M. Palko, A. Duffett, R. 
Crist, and P. A. Naugle. "Comparative evaluation of the API 20S system and 
the automicrobic system gram-positive identification card for species 
identification of streptococci." Journal of clinical microbiology 19, no. 2 
(1984): 164-168. 
38. Appelbaum PC,Jacobs MR,Palko WM,Frauenhoffer EE,A.Duffet.Accuracy 
and reproducibility of the IDS Rapid SIR system for species identification of 
streptococci.J. Clin.Microbiolo.1986;23:843-846. 
39. Gardini, Fausto, Maria Martuscelli, Marisa Carmela Caruso, Fernanda 
Galgano, Maria Antonietta Crudele, Fabio Favati, Maria Elisabetta Guerzoni, 
and Giovanna Suzzi. "Effects of pH, temperature and NaCl concentration on 
the growth kinetics, proteolytic activity and biogenic amine production of 
Enterococcus faecalis." International journal of food microbiology 64, no. 1 
(2001): 105-117. 
40. Nakajo, K., R. Komori, S. Ishikawa, T. Ueno, Y. Suzuki, Y. Iwami, and N. 
Takahashi. "Resistance to acidic and alkaline environments in the endodontic 
pathogen Enterococcus faecalis." Oral microbiology and immunology 21, no. 
5 (2006): 283-288. 
41. Martinez, S., M. Lopez, and A. Bernardo. "Thermal inactivation of 
Enterococcus faecium: effect of growth temperature and physiological state 
of microbial cells." Letters in applied microbiology 37, no. 6 (2003): 475-
481. 
42. Klein, Günter. "Taxonomy, ecology and antibiotic resistance of enterococci 
from food and the gastro-intestinal tract." International journal of food 
microbiology 88, no. 2 (2003): 123-131. 
43. Kühn, Inger, Aina Iversen, Lars G. Burman, Barbro Olsson-Liljequist, 
Anders Franklin, Maria Finn, Frank Aarestrup et al. "Comparison of 
enterococcal populations in animals, humans, and the environment-a 
European study."International journal of food microbiology 88, no. 2 (2003): 
133-145. 
44. Kapoor, Lata, V. S. Randhawa, and Monorama Deb. "Antimicrobial 
resistance of enterococcal blood isolates at a pediatric care hospital in 
India." Jpn J Infect Dis 58, no. 2 (2005): 101-3. 
45. Parvathi S, Appalaraju B.Isolation,characterization and antibiogram of 
Enterococci from clinical samples.Indian J Pathol Microbiol 2003;46(3):501-
3. 
46. Mundy, L. M., D. F. Sahm, and M. Gilmore. "Relationships between 
enterococcal virulence and antimicrobial resistance." Clinical Microbiology 
Reviews 13, no. 4 (2000): 513-522. 
47. McDonald, L. Clifford, Matthew J. Kuehnert, Fred C. Tenover, and William 
R. Jarvis. "Vancomycin-resistant enterococci outside the health-care setting: 
prevalence, sources, and public health implications." Emerging infectious 
diseases 3, no. 3 (1997): 311. 
48. Hancock, Lynn E., and Marta Perego. "The Enterococcus faecalis fsr two-
component system controls biofilm development through production of 
gelatinase." Journal of bacteriology 186, no. 17 (2004): 5629-5639 
49. Huycke, Mark M., Wendy Joyce, and Matthew F. Wack. "Augmented 
production of extracellular superoxide by blood isolates of Enterococcus 
faecalis." Journal of Infectious Diseases 173, no. 3 (1996): 743-745. 
50. -
Arrizubieta, Carme Cucarella, Marta Lamata, Beatriz Amorena, José Leiva, 
José Rafael Penadés, and Iñigo Lasa. "The enterococcal surface protein, Esp, 
is involved in Enterococcus faecalis biofilm formation." Applied and 
environmental microbiology 67, no. 10 (2001): 4538-4545. 
51. Sava, Irina G., Esther Heikens, and Johannes Huebner. "Pathogenesis and 
immunity in enterococcal infections." Clinical microbiology and 
infection 16, no. 6 (2010): 533-540. 
52. Giridhara Upadhyaya, P. M., K. L. Ravikumar, and B. L. Umapathy. 
"Review of virulence factors of enterococcus: an emerging nosocomial 
pathogen." Indian journal of medical microbiology 27, no. 4 (2009): 301. 
53. Gilmore, Michael S., Robert A. Segarra, Mary C. Booth, Charles P. Bogie, 
Lisa R. Hall, and Don B. Clewell. "Genetic structure of the Enterococcus 
faecalis plasmid pAD1-encoded cytolytic toxin system and its relationship to 
lantibiotic determinants." Journal of Bacteriology 176, no. 23 (1994): 7335-
7344. 
54. Chow, J. W., L. A. Thal, M. B. Perri, J. A. Vazquez, S. M. Donabedian, D. 
B. Clewell, and M. J. Zervos. "Plasmid-associated hemolysin and 
aggregation substance production contribute to virulence in experimental 
enterococcal endocarditis." Antimicrobial agents and chemotherapy 37, no. 
11 (1993): 2474-2477. 
55. Shankar, Viswanathan, Arto S. Baghdayan, Mark M. Huycke, Gunnar 
Lindahl, and Michael S. Gilmore. "Infection-derived Enterococcus 
faecalisstrains are enriched in esp, a gene encoding a novel surface 
protein." Infection and immunity 67, no. 1 (1999): 193-200. 
56. Singh, Kavindra V., Xiang Qin, George M. Weinstock, and Barbara E. 
Murray. "Generation and testing of mutants of Enterococcus faecalis in a 
mouse peritonitis model." Journal of Infectious Diseases 178, no. 5 (1998): 
1416-1420. 
57. Huycke, Mark M., and Michael S. Gilmore. "In vivo survival of 
Enterococcus faecalis is enhanced by extracellular superoxide production." 
In Streptococci and the Host, pp. 781-784. Springer US, 1997. 
58. Baldassarri, Lucilla, Roberto Cecchini, Lucia Bertuccini, Maria G. 
Ammendolia, F. Iosi, Carla R. Arciola, Lucio Montanaro et al. "Enterococcus 
spp. produces slime and survives in rat peritoneal macrophages." Medical 
microbiology and immunology 190, no. 3 (2001): 113-120. 
59. Mohamed, Jamal A., and David B. Huang. "Biofilm formation by 
enterococci."Journal of medical microbiology 56, no. 12 (2007): 1581-1588. 
60. Teng, Fang, Kavindra V. Singh, Agathe Bourgogne, Jing Zeng, and Barbara 
E. Murray. "Further characterization of the epa gene cluster and Epa 
polysaccharides of Enterococcus faecalis." Infection and immunity 77, no. 9 
(2009): 3759-3767. 
61. Mohamed, Jamal A., Wenxiang Huang, Sreedhar R. Nallapareddy, Fang 
Teng, and Barbara E. Murray. "Influence of origin of isolates, especially 
endocarditis isolates, and various genes on biofilm formation by 
Enterococcus faecalis."Infection and immunity 72, no. 6 (2004): 3658-3663. 
62. Morrison, Allan J., and Richard P. Wenzel. "Nosocomial urinary tract 
infections due to enterococcus: ten years' experience at a university 
hospital." Archives of internal medicine 146, no. 8 (1986): 1549-1551. 
63. Lemoine, L., and P. R. Hunter. "Enterococcal urinary tract infections in a 
teaching hospital." European journal of clinical microbiology 6, no. 5 
(1987): 574-575. 
64. Gorensek, Margaret J., Marc H. Lebel, and John D. Nelson. "Peritonitis in 
children with nephrotic syndrome." Pediatrics 81, no. 6 (1988): 849-856. 
65. Gibbs, R. S., H. M. Listwa, and R. B. Dreskin. "A pure enterococcal abscess 
after cesarean section." The Journal of reproductive medicine 19, no. 1 
(1977): 17-20. 
66. Shales DM, Lewy J, Wolinsky E. Enterococcal bacteremia wihout 
endocarditis.Arch.Intern.Med.1981;141:578-581. 
67. Garrison, R. NEAL, DONALD E. Fry, S. U. S. A. N. Berberich, and HIRAM 
C. Polk Jr. "Enterococcal bacteremia: clinical implications and determinants 
of death." Annals of surgery 196, no. 1 (1982): 43. 
68. Malone, Donald A., Renee A. Wagner, Joseph P. Myers, and Chatrchai 
Watanakunakorn. "Enterococcal bacteremia in two large community teaching 
hospitals." The American journal of medicine 81, no. 4 (1986): 601-606. 
69. Maki, Dennis G., and William A. Agger. "Enterococcal bacteremia: clinical 
features, the risk of endocarditis, and management." Medicine 67, no. 4 
(1988): 248. 
70. Moellering, Robert C., Barbara K. Watson, and Lawrence J. Kunz. 
"Endocarditis due to group D streptococci: comparison of disease caused by 
Streptococcus bovis with that produced by the enterococci." The American 
journal of medicine 57, no. 2 (1974): 239-250. 
71. Reiner, Neil E., K. V. Gopalakrishna, and Phillip I. Lerner. "Enterococcal 
endocarditis in heroin addicts." JAMA 235, no. 17 (1976): 1861-1863. 
72. Luginbuhl, Lynn m., Harley a. Rotbart, Richard R. Facklam, Martha H. Roe, 
and John A. Elliot. "Neonatal enterococcal sepsis: case-control study and 
description of an outbreak." The Pediatric infectious disease journal 6, no. 
11 (1987): 1022-1026. 
73. Sharma, S., S. Malhotra, N. J. K. Bhatia, A. Wilson, and C. Hans. "Right 
temporal otogenic brain abscess by Enterococcus faecalis-A rare case 
report."Int J Curr Microbiol App Sci 3 (2014): 101-4. 
74. Hoffmann, Stephen A., and Robert C. Moellering. "The enterococcus: 
putting the bug in our ears." Annals of internal medicine 106, no. 5 (1987): 
757-761. 
75. Doucet PopulaireF, Triell-Coat P,Dosbaa I, Andremont A, Couvarlin 
P.Inducible transfer of transposon Tn 3545 from enterococcus faecalis to 
Listeria monocyogenes in the digestive tract of gnotobiotic mice.Antimicrob 
Agents Chemother 1991;35: 185-87. 
76. Caprioli, T., F. Zaccour, and S. S. Kasatiya. "Phage typing scheme for group 
D streptococci isolated from human urogenital tract." Journal of clinical 
microbiology 2, no. 4 (1975): 311-317. 
77. CLSI.Clinical and Laboratory Standards Institute.Performance Standards for 
antimicrobial susceptibility testing. CLSI document M100-
524.Wayne,PA:Clinical and Laboratory standard Institute 2014. 
78. Rosenthal, Samuel L., and Lawrence F. Freundlich. "An aminoglycoside disk 
sensitivity test for use with enterococci." Journal of Antimicrobial 
Chemotherapy 10, no. 5 (1982): 459-462. 
79. Spiegel, Carol A. "Laboratory detection of high-level aminoglycoside-
aminocyclitol resistance in Enterococcus spp." Journal of clinical 
microbiology26, no. 11 (1988): 2270-2274. 
80. Moellering Jr, R. C., C. Wennersten, T. Medrek, and A. N. Weinberg. 
"Prevalence of high-level resistance to aminoglycosides in clinical isolates of 
enterococci." Antimicrobial agents and chemotherapy 10 (1969): 335-340. 
81. Sahm, DANIEL F., and C. A. R. M. E. N. Torres. "Effects of medium and 
inoculum variations on screening for high-level aminoglycoside resistance in 
Enterococcus faecalis." Journal of clinical microbiology 26, no. 2 (1988): 
250-256. 
82. Zervos, M. J., J. E. Patterson, S. Edberg, C. Pierson, C. A. Kauffman, T. S. 
Mikesell, and D. R. Schaberg. "Single-concentration broth microdilution test 
for detection of high-level aminoglycoside resistance in 
enterococci." Journal of clinical microbiology 25, no. 12 (1987): 2443-2444. 
83. Smyth, C. J., HELEN MATTHEWS, M. K. Halpenny, H. Brandis, and G. 
Colman. "Biotyping, serotyping and phage typing of Streptococcus faecalis 
isolated from dental plaque in the human mouth." Journal of medical 
microbiology 23, no. 1 (1987): 45-54. 
84. Morrison, D., N. Woodford, S. P. Barrett, P. Sisson, and B. D. Cookson. 
"DNA banding pattern polymorphism in vancomycin-resistant Enterococcus 
faecium and criteria for defining strains." Journal of clinical 
microbiology 37, no. 4 (1999): 1084-1091. 
85. Gordillo, M. E., K. V. Singh, and B. E. Murray. "Comparison of ribotyping 
and pulsed-field gel electrophoresis for subspecies differentiation of strains 
of Enterococcus faecalis." Journal of clinical microbiology 31, no. 6 (1993): 
1570-1574. 
86. QuednauM, Ahrne S, Molin G. Genomic relationships between Enterococcus 
faecium strains from different sources and with different antibiotic resistance 
profiles evaluated by restriction endonuclease,amalyis of total chromosomal 
DNA using ECOR1 and PVUII. Appl.Environ Microbiol, 1999 Apr, 65(4): 
1777-80. 
87. Jackson, Charlene R., Paula J. Fedorka-Cray, and John B. Barrett. "Use of a 
genus-and species-specific multiplex PCR for identification of 
enterococci."Journal of Clinical Microbiology 42, no. 8 (2004): 3558-3565. 
88. Murray, B. E. "Beta-lactamase-producing enterococci." Antimicrobial agents 
and chemotherapy 36, no. 11 (1992): 2355. 
89. Karchmer, Adolf W., Robert C. Moellering, and Barbara K. Watson. 
"Susceptibility of various serogroups of streptococci to clindamycin and 
lincomycin." Antimicrobial agents and chemotherapy 7, no. 2 (1975): 164-
167. 
90. Weinstein, Allan J., and Robert C. Moellering. "Penicillin and gentamicin 
therapy for enterococcal infections." JAMA 223, no. 9 (1973): 1030-1032. 
91. Lin, R. V. T. P., and A. L. Tan. "Enterococcus faecium with high-level 
resistance to gentamicin." The Lancet 338, no. 8761 (1991): 260-261. 
92. Uttley, AnneH C., C. H. Collins, Jay Naidoo, and R. C. George. 
"Vancomycin-resistant enterococci." The Lancet 331, no. 8575 (1988): 57-
58. 
93. Arthur, M., and Patrice Courvalin. "Genetics and mechanisms of 
glycopeptide resistance in enterococci." Antimicrobial Agents and 
Chemotherapy 37, no. 8 (1993): 1563. 
94. Perichon, Bruno, Peter Reynolds, and Patrice Courvalin. "VanD-type 
glycopeptide-resistant Enterococcus faecium BM4339." Antimicrobial agents 
and chemotherapy 41, no. 9 (1997): 2016-2018. 
95. Fines, Marguerite, Bruno Perichon, Peter Reynolds, Daniel F. Sahm, and 
Patrice Courvalin. "VanE, a new type of acquired glycopeptide resistance in 
Enterococcus faecalis BM4405." Antimicrobial agents and chemotherapy 43, 
no. 9 (1999): 2161-2164. 
96. McKessar, Stuart J., Anne M. Berry, Jan M. Bell, John D. Turnidge, and 
James C. Paton. "Genetic characterization of vanG, a novel vancomycin 
resistance locus of Enterococcus faecalis." Antimicrobial agents and 
chemotherapy 44, no. 11 (2000): 3224-3228. 
97. Zirakzadeh, Ali, and Robin Patel. "Vancomycin-resistant enterococci: 
colonization, infection, detection, and treatment." In Mayo Clinic 
Proceedings, vol. 81, no. 4, pp. 529-536. Elsevier, 2006. 
98. Praharaj, Ira, S. Sujatha, and Subhash Chandra Parija. "Phenotypic & 
genotypic characterization of vancomycin resistant Enterococcus isolates 
from clinical specimens." The Indian journal of medical research 138, no. 4 
(2013): 549. 
99. Montecalvo MA, de LancestreH,Carraher M, GedrisC, Chung M, Van Horn 
K, Wormser GP.Natural history of colonization with vancomycin resistant 
Enterococcus faecium.Infect.Control Hosp.Epidemiol.1995;16:680-685. 
100. Edmond, Michael B., Janis F. Ober, Jeffrey D. Dawson, David L. 
Weinbaum, and Richard P. Wenzel. "Vancomycin-resistant enterococcal 
bacteremia: natural history and attributable mortality." Clinical Infectious 
Diseases 23, no. 6 (1996): 1234-1239. 
101. Papanicolaou, Genovefa A., Burt R. Meyers, Jonathan Meyers, Meryl H. 
Mendelson, Wendy Lou, Sukru Emre, Patricia Sheiner, and Charles Miller. 
"Nosocomial Infections with Vancomycin-Resistant Enterococcus fuecium in 
Liver Transplant Recipients: Risk Factors for Acquisition and 
Mortality." Clinical Infectious Diseases 23, no. 4 (1996): 760-766. 
102. Eliopoulos, George M. "Vancomycin-resistant enterococci: Mechanism 
and clinical relevance." Infectious disease clinics of North America 11, no. 4 
(1997): 851-865. 
103. Cuzon, Gaëlle, Thierry Naas, Nicolas Fortineau, and Patrice Nordmann. 
"Novel chromogenic medium for detection of vancomycin-resistant 
Enterococcus faecium and Enterococcus faecalis." Journal of clinical 
microbiology 46, no. 7 (2008): 2442-2444. 
104. Hayden, M. K., G. M. Trenholme, J. E. Schultz, and D. F. Sahm. "In vivo 
development of teicoplanin resistance in a VanB Enterococcus faecium 
isolate." Journal of Infectious Diseases 167, no. 5 (1993): 1224-1227. 
105. Johnson, Caroline C., Linda Slavoski, Mary Schwartz, Phyllis May, Peter 
G. Pitsakis, Andrew L. Shur, and Matthew E. Levison. "In vitro activity of RP 
59500 (quinupristin/dalfopristin) against antibiotic-resistant strains of 
Streptococcus pneumoniae and enterococci." Diagnostic microbiology and 
infectious disease 21, no. 3 (1995): 169-173. 
106. Daly, J. S., G. M. Eliopoulos, S. Willey, and R. C. Moellering. 
"Mechanism of action and in vitro and in vivo activities of S-6123, a new 
oxazolidinone compound." Antimicrobial agents and chemotherapy 32, no. 9 
(1988): 1341-1346. 
107. Boyce, John M. "Vancomycin-resistant enterococcus: detection, 
epidemiology, and control measures." Infectious disease clinics of North 
America 11, no. 2 (1997): 367-384. 
108. Forbes BA, Sham DF, Weissfeld AS.Chapter 5. Specimen 
management.53-67. Bailey and Scott’s Diagnostic Microbiology,13th 
edition,2007, Elsevier.Mosby Publication. 
109. Vakulenko, Sergei B., Susan M. Donabedian, Anatoliy M. 
Voskresenskiy, Marcus J. Zervos, Stephen A. Lerner, and Joseph W. Chow. 
"Multiplex PCR for detection of aminoglycoside resistance genes in 
enterococci." Antimicrobial agents and chemotherapy 47, no. 4 (2003): 1423-
1426. 
110. Dutka-Malen, Sylvie, Stefan Evers, and Patrice Courvalin. "Detection of 
glycopeptide resistance genotypes and identification to the species level of 
clinically relevant enterococci by PCR." Journal of clinical microbiology 33, 
no. 1 (1995): 24-27. 
111. Karmarkar, M. G., Edwin S. Gershom, and P. R. Mehta. "Enterococcal 
infections with special reference to phenotypic characterization & drug 
resistance." Indian Journal of Medical Research 119 (2004): 22-25. 
112. Mathur, Purva, Arti Kapil, Rachna Chandra, Pratibha Sharma, and Bimal 
Das. "Antimicrobial resistance in Enterococcus faecalis at a tertiary care 
centre of northern India." Indian Journal of Medical Research 118 (2003): 25-
28. 
113. Golia, Saroj, A. R. Nirmala, and Asha SB Kamath. "Isolation and 
speciation of enterococci from various clinical samples and their antimicrobial 
susceptibility pattern with special reference to high level aminoglycoside 
resistance."International Journal of Medical Research & Health Sciences 3, 
no. 3 (2014): 526-529. 
114. Duggal, Shalini, Rajni Gaind, Neha Tandon, Manorama Deb, and Tulsi 
Das Chugh. "Comparison of an automated system with conventional 
identification and antimicrobial susceptibility testing." ISRN 
microbiology 2012 (2012). 
115. Chatzigeorgiou, Kalliopi-Stavroula, Theodoros N. Sergentanis, Sotirios 
Tsiodras, Stavros J. Hamodrakas, and Pantelis G. Bagos. "Phoenix 100 
versus Vitek 2 in the identification of gram-positive and gram-negative 
bacteria: a comprehensive meta-analysis." Journal of clinical 
microbiology 49, no. 9 (2011): 3284-3291. 
116. Mulla, Summaiya, Kinjal G. Patel, Tanvi Panwala, and Sangita 
Rewadiwala. "Prevalence of enterococci with higher resistance level in a 
tertiary care hospital: a matter of concern." therapy 1, no. 2 (2012): 3. 
117. Randhawa, V. S., L. Kapoor, V. Singh, and G. Mehta. "Aminoglycoside 
resistance in enterococci isolated from paediatric septicaemia in a tertiary care 
hospital in north India." Indian Journal of Medical Research 119 (2004): 77-
79. 
118. Sreeja, S., P. R. Sreenivasa Babu, and A. G. Prathab. "The prevalence and 
the characterization of the enterococcus species from various clinical samples 
in a tertiary care hospital." Journal of clinical and diagnostic research: 
JCDR 6, no. 9 (2012): 1486. 
119. Cuzon, Gaëlle, Thierry Naas, Nicolas Fortineau, and Patrice Nordmann. 
"Novel chromogenic medium for detection of vancomycin-resistant 
Enterococcus faecium and Enterococcus faecalis." Journal of clinical 
microbiology 46, no. 7 (2008): 2442-2444. 
120. Stamper, Paul D., Stephanie Shulder, Pearl Bekalo, Deepika Manandhar, 
Tracy L. Ross, Sharon Speser, Julie Kingery, and Karen C. Carroll. 
"Evaluation of BBL CHROMagar VanRE for detection of vancomycin-
resistant enterococci in rectal swab specimens." Journal of clinical 
microbiology 48, no. 11 (2010): 4294-4297. 
121. Murdoch, David R., Stanley Mirrett, Lizzie J. Harrell, Susan M. 
Donabedian, Marcus J. Zervos, and L. Barth Reller. "Comparison of 
microscan broth microdilution, synergy quad plate agar dilution, and disk 
diffusion screening methods for detection of high-level aminoglycoside 
resistance in enterococcus species." Journal of clinical microbiology 41, no. 6 
(2003): 2703-2705. 
122. Jain, Sarika, Ashwani Kumar, Bineeta Kashyap, and Iqbal R. Kaur. 
"Clinico-epidemiological profile and high-level aminoglycoside resistance in 
enterococcal septicemia from a tertiary care hospital in east 
Delhi."International Journal of Applied and Basic Medical Research 1, no. 2 
(2011): 80. 
123. Mendiratta, D. K., H. Kaur, V. Deotale, D. C. Thamke, R. Narang, and P. 
Narang. "Status of high level aminoglycoside resistant Enterococcus faecium 
and Enterococcus faecalis in a rural hospital of central India." Indian Journal 
of Medical Microbiology 26, no. 4 (2008): 369. 
124. Padmasini, Elango, R. Padmaraj, and S. Srivani Ramesh. "High level 
aminoglycoside resistance and distribution of aminoglycoside resistant genes 
among clinical isolates of Enterococcus species in Chennai, India." The 
Scientific World Journal 2014 (2014). 
125. Hasani, A., Y. Sharifi, R. Ghotaslou, B. Naghili, A. Hasani, M. 
Aghazadeh, M. Milani, and A. Bazmani. "Molecular screening of virulence 
genes in high-level gentamicin-resistant Enterococcus faecalis and 
Enterococcus faecium isolated from clinical specimens in Northwest 
Iran." Indian journal of medical microbiology 30, no. 2 (2012): 175. 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 
1) GRAM STAIN: 
Crystal violet: 
Crystal violet                          1.0gm 
5% sodium bicarbonate          1.0ml 
Distilled water                         99ml 
Grams iodine: 
Iodine crystal                        2.0gm 
Sodium hydroxide                10.0ml 
Distilled water                      90.0ml 
Acetone- 100% 
DILUTE CARBOL FUCHSIN- 1 in 10 dilution. 
2) BLOOD AGAR: 
Sterile defibrinated sheep blood    7ml 
Nutrient Agar                                100 ml 
         About 7ml of melted Nutrient agar, as a base into sterile petri dishes and 
allow setting. Add sterile defibrinated blood(5-7%) to Nutrient Agar, the latter 
cooled to 45-50
0
C before blood is added. Mix and pour 20ml of blood agar in the 
petridish. 
3) MAC CONKEY AGAR: 
Peptic digest of animal tissue            2.0gms 
Lactose                                              1.0gms 
Sodium taurocholate                          0.5gm 
Sodium chloride                                 0.5gm 
Neutral red                                         1% 
Agar                                                   1.5gm 
Distilled water                                   100 ml 
Dissolve the ingredients except lactose in distilled water by heating. Adjust pH 
to 7.6. Sterilize by autoclaving at 121
0
 for 15 minutes. 
4) ROBERTSON COOKED MEAT MEDIA: 
Beef infusion broth. 
Minced and dried meat. 
One part of meat is mixed with two parts of water. Cool, refrigerate and skim off 
any remaining fat. Boil for 30 minutes. Filter through two layers of gauze and 
pH is adjusted to 7.5.Dried meat particles are distributed in 15*150 mm tube to a 
height of 1.5 to 2.5cm.The filtrate is then added to get 3 to 4 parts. The tubes 
plugged and sterilized by autoclaving. 
 
5) MEDIA WITH pH 9.6: 
Agar powder           1.5-1.8gms 
Nutrient broth         100ml 
Mix the agar in nutrient broth and heat to dissolve. When cool adjust the pH to 
9.6.Sterilize by autoclaving. Pour 20ml in petridish. Dry the plate. 
6) 6.5% Sodium chloride broth: 
Peptone                     1gm 
Beef extract              0. 5gm 
Sodium chloride       6.5gm 
Glucose                    0.1gm 
Distilled water         100 ml 
The above ingredients are mixed by boiling, Sterilized by autoclaving at 
121
0 
C for 15 minutes.  
7) BILE AESCULIN AGAR: 
Beef extract               0.3gm 
Peptone                     0.5gm 
Bile salts                    4gm 
Aesculin                     0.1gm 
Ferric citrate               0.05gm 
Agar                           1.5gm 
Distilled water            100ml 
pH                                7.0 
         The above ingredients are mixed by boiling and sterilized by autoclaving at 
121
0 
C for 15 minutes. Dispensed in tubes and allowed to cool in a slanted 
position. 
8) PYR media: 
Casein peptone               2.0gm 
Beef heart infusion         0.3gm 
Sodium carbonate           0.25gm 
Dextrose                          0.2gm 
Sodium chloride              0.2gm 
Disodium phosphate                                    0.04gm 
L- pyroglutamic acid-beta naphthylamide   0.01gm 
Distilled water                                              100ml 
pH                                                                 7.8 
The above ingredients are mixed and sterilized by autoclaving at 121
0
C at 
15 minutes. These are dispersed in tubes and stored. 
9) ARGININE DECARBOXYLASE BROTH: 
Peptone                                    0.5gm 
Beef extract                             0.5gm 
Bromocresol purple                 0.001gm 
Cresol red                                0.0005gm 
Glucose                                    0.05gm 
Pyridoxal                                 0.0005gm 
Distilled water                         100 ml 
pH                                            6.0 
        To the above 10gm of the L(levo) form of the amino acid arginine is added 
and dispensed in tubes.The above contents are autoclaved at121
0
C for 15 
minutes. 
10) POTASSIUM TELLURITE AGAR: 
Peptone                                 1gm 
Sodium chloride                    0.5gms 
Beef extract                            0.5gm 
12) CARBOHYDRATE FERMENTATION MEDIA: 
Peptone water                        100ml 
Sugar                                      1ml 
Andrade indicator                  1ml 
      The above are distributed in tubes along with durhams tube and autoclaved at 
115
0
C for 10 minutes. 
      The sugars used are mannitol, arabinose, raffinose, sorbitol, lactose and 
sucrose. 
13) MULLER HINTON AGAR: 
Casein acid hydrolysate                        1.75gm 
Beef heart infusion                                0.2gm 
Starch                                                    0.15gm 
Agar                                                       1.7gm 
Distilled water                                       100ml 
pH                                                          7.3 
      The above ingredients are boiled to dissolve and sterilized by autoclaving at 
121
0
 C for 15 minutes .These are poured in petridish, dried and stored. 
 
Agar                                       2gm 
Potassium tellurite                0.04gm 
Distilled water                      100ml 
pH                                         7.2 
       The basal ingredients are mixed by boiling, sterilized at 121
0
C for 15 
minutes. To this potassium tellurite solution is added , mixed and poured in 
petridish.  
11) PYRUVATE MEDIUM: 
Tryptone                                1gm 
Yeast extract                          0.5gm 
Dipotassium phosphate          0.5gm 
Sodium chloride                     0.5gm 
Agar                                        1gm 
Sodium pyruvate                     1gm 
Bromothymol blue ethanolic solution: 4mg/ml 
pH                                          7.1-7.4 
      The solid ingredients are dissolved by heating, cooled and the indicator 
solution is added. The pH is adjusted and sterilized by autoclaving at 121
0
 C. 
These are then dispensed in tubes and allowed to cool as slopes. 
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